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ABSTRACT 
 
 
 
Background: 
 The objective of the study was  to assess the association between diabetes and infection. 
Methods:  
A systematic review and meta-analysis was conducted to summarize and quantify the 
association between diabetes and the risk of infections in the existing literature. Second, a 
cohort study was done to estimate the association between diabetes and infections 
occurring in primary care.  
Results: 
The systematic review and meta-analysis demonstrated that diabetes is associated with an 
increased risk of infection. Results were generally consistent across types of infections. 
Findings from the cohort study suggest that patients with diabetes have a small increased 
risk of developing certain infections compared to patients without diabetes in primary 
care. 
Conclusion:  
Diabetes is associated with an increased risk of infections. The relationship varies 
according to type of infection present. However, more research is needed to determine the 
implications of patient characteristics such as BMI and glycemic control on the risk of 
infections. 
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Chapter 1 
 
Introduction 
 
 
1.1 Background: 
 
 
1.1.1 Burden of Diabetes Mellitus: 
Diabetes mellitus is a serious chronic condition with potentially devastating 
complications that affects all age groups worldwide. In the year 2015 more than 415 
million people were diagnosed with diabetes mellitus globally. According to the 
International Diabetes Federation (IDF) this number is expected to rise to more than 640 
million people by the year 2040 (1). Canada is one of the countries that will be 
significantly affected by this change. As of 2014, the estimated prevalence of diabetes in 
Canada was 6.7% of the population reflecting over 2 million Canadians living with 
diabetes (2).  
Diabetes and its complications increase costs and service pressures on the healthcare 
system.  Among adults aged 20 to 49 years, those who had diabetes were 2 to 3 times 
more likely to see a family physician or a specialist (2). Also, people with diabetes were 3 
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times more likely to require hospital admission in the preceding year with longer lengths 
of stay compared to those without diabetes (2). People with diabetes are over 3 times 
more likely to be hospitalized with cardiovascular disease, 12 times more likely to be 
hospitalized with end stage renal disease(ESRD) and over 20 times more likely to be 
hospitalized for a nontraumatic lower limb amputation compared to the general 
population (2). Obesity, hypertension, and dyslipidemia are the most commonly 
distinctive comorbidities associated with diabetes. However, there are other conditions 
found at higher rates in people with diabetes; depression, obstructive sleep apnea, fatty 
liver disease, cancer, fractures, cognitive impairment, low testosterone in men, 
periodontal disease and hearing impairment (3). Diabetes is the sixth leading cause of 
death in Canada (4). By 2050, the number of deaths directly attributable to diabetes in 
Canada is likely to increase to almost 17,500 deaths annually (5).  
 
 
1.1.2 Definition: 
Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia 
due to defective insulin secretion, defective insulin action or both (6). Diabetes is 
associated with relatively specific long-term complications, due to persistence of 
hyperglycemia, affecting several body organs mainly the nerves, kidneys, eyes, as well as 
an increased risk for cardiovascular disease. Diabetes can be diagnosed based on glycated 
hemoglobin (A1C) criteria, fasting plasma glucose, random plasma glucose, or a 2-hour 
plasma glucose value after a 75 g oral glucose tolerance test (7,8).  
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1.1.3 Classification: 
Diabetes can be classified into several categories. Type 1 diabetes encompasses diabetes 
that is primarily a result of pancreatic beta cell destruction and is prone to ketoacidosis 
(6). This form, previously called “insulin-dependent diabetes” or “juvenile-onset 
diabetes,” accounts for 5–10% of diabetes (9). It includes cases due to an autoimmune 
process and those for which the etiology of beta cell destruction is unknown.  
Type 2 diabetes, previously referred to as “noninsulin- dependent diabetes” or “adult 
onset diabetes,” accounts for 90–95% of all diabetes (9). Type 2 diabetes may range from 
predominant insulin resistance with relative (rather than absolute) insulin deficiency to a 
predominant secretory defect with insulin resistance (6). At least initially, and often 
throughout their lifetime, these individuals may not need insulin treatment to survive. 
Distinguishing between type 1 and type 2 diabetes is important because management 
strategies differ, but it may be difficult at the time of diagnosis in certain situations. 
Clinical judgment with safe management and ongoing follow-up is a prudent approach. 
In the past, gestational diabetes was defined as any degree of glucose intolerance that was 
first recognized during pregnancy (10), regardless of whether the condition may have 
predated the pregnancy or persisted after the pregnancy. A more accurate definition was 
undertaken. Gestational diabetes is diabetes diagnosed in the second or third trimester of 
pregnancy that is not clearly overt diabetes. Women with diabetes in the first trimester 
would be classified as having type 2 diabetes (9). 
Other specific types include a wide variety of relatively uncommon conditions, primarily 
specific genetically defined forms of diabetes or diabetes associated with other diseases or 
drug use (6,9). 
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In 1997 and 2003, the Expert Committee on Diagnosis and Classification of Diabetes 
Mellitus (10,11) recognized a group of individuals whose glucose levels did not meet the 
criteria for diabetes but were too high to be considered normal. “Prediabetes” is a 
practical and convenient term referring to impaired fasting glucose, impaired glucose 
tolerance (12) or an A1C of 6.0% to 6.4%, each of which indicates an increased risk for 
the future development of diabetes and its complications. Impaired fasting glucose and 
impaired glucose tolerance should not be viewed as clinical entities in their own right but 
rather risk factors for diabetes and cardiovascular disease. Impaired fasting glucose and 
impaired glucose tolerance are associated with obesity (especially abdominal or visceral 
obesity) (13), dyslipidemia with high triglycerides and/or low HDL cholesterol, and 
hypertension. 
 
 
1.1.4 Management Strategies: 
People with type 1 diabetes require insulin for their survival. Standard treattment should 
be treated with multiple injections (three to four injections per day of different types of 
insulin) or a continuous subcutaneous insulin infusion system (14). Type 2 diabetes has 
traditionally been treated in a stepwise manner, starting with lifestyle modifications (such 
as diet and  exercise)  and later with pharmacotherapy. Several classes of oral agents are 
available for clinical use. These mainly include insulin seceratgogues, insulin sensitizers, 
and drugs that delay the absorption of carbohydrates from the gastrointestinal tract. Over 
time, many patients with type 2 diabetes will require insulin therapy. There are currently 
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seven broad classes of antidiabetic drugs currently approved for use in Canada: Insulin, 
Metformin, Sulfonylureas, Meglinides, α-Glucosidase Inhibitors, Thiazolidinediones, 
Incretins and Sodium Glucose Cotransporter 2 Inhibitors (14,15). 
 
 
1.1.5 Complications: 
Diabetes is associated with significant dysfunction of numerous metabolic pathways, 
which in the long run, will lead to complications that involve multiple systems of the 
body. Cardiovascular disease is the major cause of morbidity and mortality for 
individuals with diabetes. In fact, cardiovascular disease is the primary cause of death 
among people with type 1 and type 2 diabetes (16-18).  
Hypertension affects the vast majority of individuals with type 2 diabetes and many of 
those with type 1 diabetes. (19) Diabetes is a considerable independent risk factors for 
myocardial infarction. Compared to individuals without diabetes, patients with diabetes 
have a 3-fold increased risk of acute coronary syndrome (20), and a 2-fold increased short 
and long-term mortality (21-24). Estimates of risk of ischemic stroke in people with 
diabetes range from a 2- to 3-fold increase in men and a 2- to 5-fold increase in women 
(25,26). Diabetes also doubles the risk of stroke recurrence, and stroke outcomes are 
significantly worse among patients with diabetes, with increased hospital and long-term 
stroke mortality, more residual neurological and functional disability, and longer hospital 
stays (27). 
Heart failure, both systolic and diastolic, is also more prevalent in people with diabetes. It 
is recognized that diabetes can cause heart failure independently of ischemic heart disease 
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by causing a diabetic cardiomyopathy (28). Epidemiological studies have shown that the 
incidence of heart failure is 2- to 4-fold higher in people with diabetes compared to those 
without diabetes (29,30). 
Another common finding in people with diabetes is kidney disease. Up to half of patients 
with diabetes demonstrate signs of kidney damage in their lifetime (31-33). Diabetes is 
the leading cause of kidney disease in Canada (34). Diabetic retinopathy is the most 
common cause of new cases of legal blindness in people of working age (35). Glaucoma, 
cataracts, and other disorders of the eye occur earlier and more frequently in people with 
diabetes. Previous data showed the prevalence rate of proliferative retinopathy to be 23% 
in people with type 1 diabetes, 14% in people with type 2 diabetes and on insulin therapy, 
and 3% in people receiving oral antihyperglycemic therapies (36). Neuropathy is yet 
another common complication with diabetes. Detectable sensorimotor polyneuropathy 
will develop within 10 years of the onset of diabetes in 40% to 50% of people with type 1 
or type 2 diabetes (37). While clinical neuropathy is uncommon in people with type 1 
diabetes within the first 5 years after the onset of diabetes, people with type 2 diabetes 
may have neuropathy at the time of diagnosis (38). Foot complications are a major cause 
of morbidity and mortality in persons with diabetes and contribute to increased healthcare 
utilization and costs (39-41).  
In addition to these comorbidities, diabetes is also associated with other diseases or 
conditions at rates higher than those in people without diabetes (14). Erectile dysfunction 
affects approximately 34% to 45% of men with diabetes(42). Recent reports describe up 
to one-third of newly diagnosed men with diabetes have erectile dysfunction at 
presentation (43), with upward of 50% of men having erectile dysfunction  by year 6 after 
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diagnosis (44). Diabetes is associated with increased risk of cancers of the liver, pancreas, 
endometrium, colon/rectum, breast, and bladder (45). Hip fracture risk is significantly 
increased in both type 1 and type 2 diabetes in both sexes (46). Type 1 diabetes is 
associated with osteoporosis, but in type 2 diabetes an increased risk of hip fracture is 
seen despite higher bone mineral density (47). Other conditions have been reported to 
occur more often in people with diabetes compared to people without, such as hearing 
impairment (48), obstructive sleep apnea (49-51), fatty liver disease (52,53), cognitive 
decline and dementia (54,55), as well as low testosterone levels in men (56). Such 
coexisting conditions and dysglycemia associated with diabetes, and the various 
treatments associated with these diseases, may also impact the susceptibility to infections 
in patients with diabetes.  
Diabetes not only increases an individual’s risk of numerous complications, it also 
decreases their quality of life and life expectancy (5-10 years) (57). Furthermore, the 
impact of living with diabetes extends to their families through economical and emotional 
burden, and society as a whole which reflects in an increase in healthcare system 
expidenture with 12% of global expidenture is spent on diabetes (>670 billion dollars) 
(1,58).  
 
 
1.1.6 Diabetes and Infection: 
Infection is a significant complication in patients with diabetes, hence it contributes to the 
morbidity, mortality and financial burden associated with the disease.  For example, a 
cohort study conducted in the United States that examined diabetes and risk related 
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mortality, found infection related deaths in patients with diabetes to be almost 3 times 
higher than in patients without diabetes (59). Another study in Northern California,  
compared one year medical care costs for people with diabetes to those without and found 
that there was almost an excess cost of 5 million dollars spent due to infections (60).  
In addition to an increased risk of infection-related morbidy and mortality, it has been 
suggested that people with diabetes may be more susceptible to developing infections 
compared to those without diabetes. Although some rare infections have been shown to 
be more prevalent in people with diabetes, (e.g., pyelonephritis, malignant otitis externa, 
mucormycosis, etc.) (61), the association between diabetes and incident common 
infections is less clear.  
 
Immunologic research has demonstrated several defects in host immune defense 
mechanisms in people with diabetes. Phagocytic capabilities of neutrophils are adversely 
affected by hyperglycemia, including impaired migration, phagocytosis, intracellular 
killing, and chemotaxis (62,63). Besides generalized impairments of immunity, other 
nonimmunologic, anatomically specific factors may contribute to an increased infection 
risk. For example, macrovascular disease and microvascular dysfunction may result in 
compromised local circulation leading to delayed response to infection and impaired 
wound healing (64). Unawareness of lower extremity trauma due to sensory neuropathy 
may result in inadequate attention to minor wounds and subsequent increased infection 
risk. Incomplete bladder emptying due to autonomic neuropathy permits urinary 
colonization by microorganisms, where high glucose concentration in the urine promotes 
the growth of some microorganisms (65). 
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The difficulties associated with estimating the actual risk of infection in diabetic patients 
are mainly due to the fact that diabetes is not solely a disturbance of glucose metabolism 
but instead a chronic inflammatory condition characterized by multiple alterations in lipid 
profiles and neuropathy as well as chronic vascular and renal diseases, with each of these 
changes altering the response to pathogens (66,67). The biological mechanisms described 
above are likely similar irrespective of the type of diabetes, especially in those with long 
standing disease; however, it is possible that the association between diabetes and 
infection may vary by etiology of diabetes. 
 
Several studies have suggested that people with diabetes are at an increased risk of 
infection-related mortality (68,69,70), however very few studies have explored the 
relationship between diabetes and susceptibility to infections. Muller et al., conducted a 
12 month cohort study measuring the increased risk of infections in adults with diabetes 
compared to those without (71). The study concluded there was an increased risk of 
infections (respiratory tract infection, urinary tract infection, skin and mucous membrane 
infection) in patients with diabetes,. However, there are several limitations worth 
mentioning. First the comparator group was patients without diabetes but with 
hypertension. They argued that  these patients formed a good comparator group due to the 
need of regular check ups, providing regular follow up data compared to patients with 
diabetes. Moreover, they state that there is no known link between hypertension and 
infection. However, there is some evidence between cardiovascular disease and infection 
(72-75). Second, the age cut-off for diabetes diagnosis was 35 years arguing that it’s 1-
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2% in type diabetes potentially excluding younger patients with diabetes. Finally their 
outcome only included 3 types of infections; urinary tract, respiratory tract, and skin and 
mucous membrane infections.  
Similarly Shah and Hux examined the association between diabetes and infection (68). 
They quantified the risk of infections and the mortality attributed to infectious disease in 
patients with diabetes. The risk ratio for infection in diabetics versus non-diabetics for 
infections was 1.21 (99% CI 1.20 –1.22). However, the study used an administrative 
dataset not primarily collected for research purposes and therefore missing critical 
information on confounders (glycemic control, comorbidities, life style factors, body max 
index, etc.).  Also the study duration was only 1 year long. 
 
Yet, not all studies agree on the presence of a relationship between diabetes and infection 
(76-78). In a case-control study Lipsky et al studied risk factors for acquiring 
pneumococcal infections in a general medical clinic. Diabetes was not shown to be 
among the risk factors for pneumococcal infections (76). However, the authors do state 
that the study population was not ideal considering them to be presumably high risk; 
elderly, from lower socioeconomic strata, and having several chronic medical conditions. 
Moreover, due to reliance on medical records, the study may have missed cases of 
pneumococcal infections, and undetectable pneumococcal vaccinations because of poor 
documentation. In another observational study, Dunkel et al examined risk factors for 
stump infection after lower limb amputation (77). Similarly, diabetes was not considered 
a risk factor for infection. However, what limits the extrapolation of the findings is that 
the study population was taken from a single institution in high income country. In 
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addition, all patients were given a single dose of prophylaxis antibiotic before surgery. 
The choice of antibiotic might differ between surgeons and if they treated patients with 
diabetes differently. This may have affected the occurrence of the outcome. 
 
Although previous studies suggest that certain infections are more common in patients 
with diabetes, there still seems to be lack of current knowledge with regards to the 
association of diabetes with certain types of infections, presence in primary care, and the 
magnitude of this relationship. The focus of the current thesis is to address these 
important points. 
 
 
 
1.2 Objectives: 
 
The aim of this thesis is to address the current knowledge gap described above 
surrounding the relationship between diabetes (all types) and the risk of infection. 
Infection will be classified according to anatomical location of infection (local or 
generalized) and infectious agent (viral or bacterla/parasites). This will be achieved 
through two studies. The first study will summarize the literature describing the 
relationship between diabetes and the risk of infection using standard systematic review. 
Furthermore, the findings from published studies will be pooled into a summary risk 
estimate using standard meta-analysis techniques. The second study will estimate the 
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association between diabetes and the occurrence of infection within a primary care setting 
using a cohort study design. It will focus on common infections within primary care 
settings. Specific questions include: 
 
Primary research question: What is the association between a new or current diagnosis of 
diabetes and common infectious diseases compared to those without diabetes? 
 
Secondary research questions: In a primary care setting, compared to non-diabetics, what 
is the association between a new or current diagnosis of diabetes and the following 
infectious diseases? 
 
1. Head and neck infections 
2. Respiratory tract infections 
3. Gastrointestinal infections 
4. Genitourinary tract infections 
5. Skin and soft tissue infections 
6. Musculoskeletal infections  
7. Viral infections 
 
Determining a relationship between exposure and outcome to be causal or non-causal is 
crucial in epidemiological research. A group of conditions necessary to be present to 
provide the evidence of a causal relationship from non-causal are known as Hill’s criteria 
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(79). The criteria are as follows; strength, consistency, specificity, temporality, biological 
gradient, plausibility, coherence, experimental evidence and analogy. At the end of this 
thesis, it will be determined if and how the results of both studies meet these criteria. 
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Chapter 2: 
 
Diabetes and the Association of Infection: A Systematic Review 
and Meta-Analysis of Observational Studies  
 
 
 
2.1 Introduction 
 
The International Diabetes Federation estimates that there were almost 400 million people 
living with diabetes through out the world in 2014. The prevalence of diabetes is expected 
to increase to more than 590 million people by the year 2035 (1). Well-known 
complications of diabetes include microvascular (retinopathy, neuropathy, nephropathy) 
and macrovascular (coronary heart disease, cerebrovascular disease, and peripheral 
vascular disease) complications (2); however, there are numerous lesser-known 
complications. For example, diabetes is associated with increased rates of certain 
infection (3-5). Impairment of the immune system in people with diabetes such as 
impaired phagocytic function may be responsible for this increased risk of infection, 
although there is still some controversy around this relationship (4-8). Certain infections 
are more prevalent in people with diabetes (9). Studies have indeed suggested that 
individuals living with diabetes are at an increased risk of infection-related mortality 
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(10,11); this could explain why some physicians believe that patients with diabetes are 
more susceptible to infections, and tend to admit these patients to the hospital (3). 
However, not all studies support this association (12,13). 
 
Although previous studies suggest that certain infections are more common in patients 
with diabetes, there is still a lack of substantive evidence to document the magnitude of 
this association. It is unclear whether diabetes is associated with an increase in the 
incidence of infections. To our knowledge, there has not been an attempt to summarize 
the existing evidence of the association between diabetes and infections, through a 
systematic review and meta-analysis. The justification for this review is as follows; it will 
help clarify the magnitude and precision of the effect; it will address gaps with regards to 
the current state of knowledge about the association between diabetes and certain types of 
infections; it will quanitify the heterogeneity among studies; and it will measure the 
quality of existing evidence on this association. Therefore, we aimed to to provide a 
rigourous summary of the evidence on the incidence of different types of infection (head 
and neck, respiratory, gastrointestinal, genitourinary, skin and soft tissue, musculoskeletal 
and viral) in patients with and without diabetes through conducting a comprehensive 
systematic review and meta-analysis. 
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2.2 Methods 
 
 
2.2.1 Study Design: 
We evaluated the relationship between diabetes and incident infections by conducting a 
systematic review and meta-analysis. The review was conducted according to Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-
analysis of Observational Studies in Epidemiology (MOOSE) guidelines during all stages 
of design, implementation and reporting (14,15).  
 
 
2.2.2 Eligibility Criteria: 
This review included observational studies assessing the association between diabetes and 
incident infections up to May 2014. Study designs that were eligible for inclusion were 
cohort studies, case-control studies, nested case-control or case-cohort studies. Other 
study designs such as systematic reviews and meta-analyses, case series, case reports, or 
cross-sectional studies were excluded from this review. Studies were included if the 
population studied was 18 years and older. Younger populations were excluded due to the 
fact that the immune system of this category is still developing, and this could affect our 
outcome of interest (16,17). Studies were required to report the number of incident 
infections in patients with diabetes and in patients without diabetes. Classification of the 
type of diabetes was based on the definition used in each study. Studies including any 
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type of diabetes were eligible including type 1 diabetes, type 2 diabetes, gestational 
diabetes, other, and unspecified diabetes.  
 
 
2.2.3 Outcomes: 
Outcomes were categorized in the following categories: infection (non specific), 
respiratory tract infections (RTI) (upper and lower), genitourinary tract infections (GU), 
skin and soft tissue infections (SSTI), gastrointestinal infections (GI), head and neck 
infections (H&N), viral infections, and any other infections not classified here. An 
outcome was placed into one of these body system categories, unless was specified by the 
study to be viral it was placed in the viral infection category. 
 
 
2.2.4 Search Strategy:  
The search strategy was carried out in collaboration with a research librarian experienced 
in systematic reviews. The following biomedical databases were searched from inception 
to December 31, 2013; PubMed, EMBASE, The Cochrane Library, International 
Pharmaceutical Science, and Web of Science. MeSH and free-text terms were used to 
search PubMed.  EMTREE and free-text terms were used to search EMBASE.  In 
searching the Cochrane Library, MeSH terms were used as well as free-text terms to 
capture items not indexed with MeSH.  The remaining databases were searched using 
free-text terms. The search was restricted to English language. See Appendix 2.A for a 
sample of the search strategy. 
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2.2.5 Study Selection and Data Extraction:  
Two independent reviewers screened titles and abstracts, and then went on to screen full 
texts. Identification of relevant studies was through use of a standardized study 
eligibility/relevance form. Discrepancies were resolved by consensus. If consensus was 
not achieved, a third reviewer was consulted. Data was extracted by one reviewer using a 
predesigned form information that included first author, contact details, journal citation, 
year of publication, study design, funding, sample size, data set used, study location and 
duration, duration of follow up, study population characteristics, statistical analysis used, 
the study specific measure of association, and the type of exposure (Appendix 2.B). An 
independent reviewer verified the accuracy of the extracted data. 
 
 
2.2.6 Assessment of Risk of Bias: 
The quality of the observational studies was appraised using the Newcastle-Ottawa 
Quality Assessment Scale (NOS) (18) according to the procedures recommended in the 
Cochrane Handbook of Systematic Reviews. One author assessed the methodological 
quality of all the selected studies. The NOS includes a “star system” in which a study is 
judged on three domains: selection of the study groups (four items); comparability of the 
groups (two items); and ascertainment of either the exposure or outcome (three items). If 
any item of NOS (for example, case definition or exposure ascertainment) is not reported, 
a zero score is given. Studies score one star for each area addressed, with scores between 
0 and 9 (the highest level of quality). As per the NOS scale, study quality was classified 
according to the study score into poor (score 0-3), moderate (score 4-6) and high quality 
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(score 7-9). 
 
 
2.2.7 Data Analysis: 
For dichotomous outcome data, the results are expressed as odds ratio (OR) with 
corresponding 95% confidence intervals (CI). For continuous outcome data, the results 
are expressed as weighted mean difference (WMD) with 95% CIs, or as standardized 
weighted mean difference if outcomes are conceptually the same but measured in 
different ways.   
 
As this review included only observational studies, we expected heterogeneity between 
studies, results were pooled across these studies using a random effects model. 
Heterogeneity was tested using the Chi-squared test and measured using the I-squared 
test. The Chi-squared test evaluates the observed differences in the results and whether 
they are compatible with chance alone. The I-squared test is used to quantify the 
inconsistency across studies. Sensitivity analyses were undertaken to explore the 
influence of different variables on the overall estimate of effect and as potential sources 
of heterogeneity including: study design (cohort versus case-control studies), quality of 
the study (low, moderate, high), sample size, patient characteristics, and exposure and 
outcome. Moreover, funnel plots were generated to assess the potential for publication 
bias. Analysis was conducted using Stata software (version 12.0). 
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2.3 Results 
 
The study selection process is shown in Figure 1. There were a total of 345 studies: 243 
cohort studies and 102 case-control studies. Most of the studies were conducted in North 
America (55%) followed by Europe (29%). The mean age of the participants was 61 
years and ranged from 26 to 80 years. Specific and unspecified infections were identified 
from the included articles. Some studies reported a specific infection, while others 
reported multiple infections. Of all infections measured in the analysis, almost 45% were 
skin and soft tissue infections, followed by respiratory tract infections (9%) and 
genitourinary infections (8%).  
According to the Newcastle-Ottawa Quality Assessment Scale (NOS), most of the studies 
(80.9%) included were of moderate quality (score 4-6). Other infections identified and 
characteristics of the studies are provided in Table 1. Table 2 clarifies specific infections 
reported by included studies. Types of infection with the odds ratio and 95%CIs found in 
this review are presented in Figure 2 (A-D). Funnel plots to express publication bias are 
shown in Appendix 2.C (1-8). 
 
 
2.3.1 Skin and Soft Tissue Infections: 
Our review found 176 studies (140 cohort studies, 36 case-control studies) that evaluated 
the association between diabetes and skin and soft tissue infections (SSTI). The pooled 
crude odds ratio (cOR) for an SSTI from cohort studies was 2.09 (95% CI 1.92-2.29), 
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with a comparable pooled adjusted odds ratio (aOR) of 2.16 (95% CI 1.95-2.39). 
Substantial between-study heterogeneity as indicated by high I2 values was observed for 
both crude and adjusted results (I2 = 91.8%,  I2 = 95.3% respectively). As for case-control 
studies, the cOR was 2.89 (95% CI 2.24-3.75), and the aOR was 2.61 (95% CI 2.17-3.13). 
Heterogeneity was less for the crude result (I2 = 74.8%), and was not present for the 
adjusted result (I2 = 0%). To decrease the heterogeneity between results, since skin and 
soft tissue infections is a relatively broad category and based on the studies found, these 
infections were categorized into surgical site infections (SSI) and other skin and soft 
tissue infections. As shown in Table 2, the results showed a positive association with 
diabetes, but heterogeneity was not decreased for the cohort studies for both groups (SSI: 
cOR 2.09, 95% CI 1.90-2.31, I2 = 91.4%, aOR 2.33, 95% CI 2.03-2.67, I2 = 93.9%; Other 
SSTI: cOR 2.22, 95% CI 1.67-2.95, I2 = 91.8%), and was less for the case-control studies 
(SSI: cOR 3.12, 95% CI 2.37-4.11, I2 = 0%, aOR 2.62, 95% CI 2.15-3.20, I2 = 0%; Other 
SSTI: cOR 1.69, 95% CI 1.05-2.72, I2 = 55.8%). Moreover, to lessen the marked 
heterogeneity, the 2 subgroups were further divided. SSI was categorized according to 
type of surgery into 9 categories. The results of each of these categories are shown in 
Table 3.  
 
 
2.3.2 Respiratory Tract Infections: 
Meta-analyses of the 49 study results of respiratory tract infections (RTI) (cohort 
studies=35, case-control studies=14) showed a positive association with diabetes. For 
cohort studies the (cOR) was 1.46 (95% CI 1.32-1.61) with considerable heterogeneity (I2 
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= 84.9%), and the (aOR) was 1.35 (95% CI 1.28-1.43) with even higher heterogeneity (I2 
= 97.8%). Case-Control studies showed a (cOR) 2.06 (95% CI 1.71-2.48), and (aOR) 
1.62 (95% CI 1.37-1.92). Heterogeneity was high as well for crude and adjusted results 
(I2 = 95%, and I2 = 85.9% respectively). Those infections were categorized into 3 
subgroups; upper respiratory tract, lower respiratory tract and unspecified. Lower 
respiratory tract infections were further classified into tuberculosis and pneumonia to 
decrease the degree of heterogeneity between the studies. Details are shown in Table 4. 
 
 
2.3.3 Genitourinary Tract Infections: 
33 cohort studies found a cOR of 2.05 (95% CI 1.83-2.31, I2 = 92.4%) and an aOR of 
1.61 (95% CI 1.42-1.83, I2 = 99.2%). Results of 11 case-control studies reported a cOR of 
3.06 (95% CI 2.21-4.23, I2 = 81.2%), and an aOR of 2.42 (95% CI 1.61-3.66, I2 = 83.7%). 
This group was divided into urinary and genital. Each of these categories was further 
classified into subgroups (Table 5). 
 
 
2.3.4 Blood-Stream Infections: 
An association was apparent after adjustment between blood-stream infections and 
diabetes. 31 cohort studies reported a cOR of 1.75 (95% CI 0.84-3.65, I2 = 99.7%) and an 
aOR of 1.73 (95% CI 1.49-2.01, I2 = 94.2%). 10 case-control studies demonstrated a 
higher association with a cOR of 2.77 (95% CI 2.24-3.42, I2 = 49.7%) and an aOR was 
2.40 (95% CI 1.68-3.42, I2 = 71.7%). Blood stream infections were also grouped 
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according to type of patients (Table 6). 
 
 
2.3.5 Viral Infections: 
Viral infections included 14 studies (cohort studies=10, case-control studies=4). The 
analysis of cohort studies revealed a cOR of 1.45 (95% CI 1.29-1.64, I2 = 66.9%) and an 
aOR of 1.29 (95% CI 1.13-1.46, I2 = 97.7%). Case-control studies showed a cOR of 1.13 
(95% CI 0.43-2.93, I2 = 99.9%) (Table 7). 
 
 
2.3.6 Head and Neck Infections: 
5 studies (cohort studies=3, case-control studies=2) reported head and neck infections 
(H&NI). Cohort studies gave a cOR of 1.33 (95% CI 1.08-1.65, I2 = 29.9%), and an aOR 
of 1.17 (95% CI 1.13-1.22, I2 = 45.4%). Case-control studies showed a cOR of 1.55 (95% 
CI 0.22-11.10, I2 = 80.7%) (Table 8). 
 
 
2.3.7 Gastrointestinal Infections: 
There were 4 cohort studies and 6 case-control studies that reported a gastrointestinal 
infection. Cohort studies suggested an inverse relationship with a cOR of 0.79 (95% CI 
0.66-0.94, I2 = 0%), but the aOR was 1.48 (95% CI 1.40-1.57, I2 = 64.5%). However, 
case-control studies showed a stronger association with a cOR of 2.44 (95% CI 1.26-4.71, 
I2 = 89.9%) and an aOR of 3.61 (95% CI 2.94-4.43, I2 = 0%) (Table 9). 
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2.3.8 Bone Infections: 
7 studies (cohort studies=5, case-control studies=2) reported bone infections. Cohort 
studies gave a cOR of 2.43 (95% CI 1.48-3.99, I2 = 0%). There was insufficient data to 
pool results for the case-control studies here. 
 
 
2.3.9 Unspecified Infections: 
There were 67 studies (cohort studies=52 studies, case-control=15 studies) that reported 
infections with no specification of type as the outcome. The cOR was 1.91 (95% CI 1.64-
2.23, I2 = 90.3%) and aOR was 1.81 (95% CI 1.64-2.00, I2 = 99.6%) for cohort studies. As 
for case-control, the cOR was 2.66 (95% CI 1.84-3.83, I2 = 73.7%) and aOR was 3.81 
(95% CI 2.88-5.04, I2 = 0%). This was further analyzed according to types of patients 
(Table 10). 
 
 
2.3.10 Other infections: 
The pooled cOR for the 2 case-control studies that reported zygomycosis was 8.21 (95% 
CI 3.45-19.57, I2 = 0%).  
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2.4 Discussion 
 
This quantitiative systematic review examined the association between diabetes and 
different types of infections. A total of 345 observational studies were identified that 
presented the existing evidence on the relationship between the diabetes and development 
of an infection. A persistent positive association was found when examining various 
classfications of infections and diabetes.  The results from individual studies were 
heterogeneous, which might reflect differences in study quality, the populations studied 
and how diabetes and infection were measured. 
 
Although the association between diabetes and the risk of developing different types of 
infections has long been postulated (9,19-21), convincing quantitative evidence has been 
lacking especially for common infections. In general a positive association between 
diabetes and infections is biological plausible given that certain microorganisms are 
known to be more common in patients with diabetes, mainly Staphylococcus, Group 
A&B Streptococcus (22-25). Moreover, hyperglycemia decreases function of neutrophils 
and monocytes by way of impaired chemotaxis, adherence, phagocytosis and other 
immune system impairment (5-7,26-28).  
 
Moveover, there may be other mechanisms at play that increase the risk of certain types 
of infections in those with diabetes. Specifcally, diabetes is known to affect healing 
(29,30), and hyperglycaemia affects coagulation and fibrinolytic function(31), lipid 
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metabolism and endothelial function (32,33) thereby leading to increased skin and soft 
tissue infections. Persons with diabetes are also susceptible to pulmonary infections due 
to an increased risk of aspiration secondary to gastroparesis, diminished cough reflex, and 
higher rates of obstructive sleep apnea (34-36). Impaired lung functions in these patients 
contribute to acquiring this type of infection as well (37,38). This impairment is believed 
to involve microangiopathic changes in the basement membrane of pulmonary blood 
vessels and respiratory epithelium, as well as non-enzymatic glycosylation of tissue 
protein (39-42). Several factors are thought to predispose diabetic subjects to 
genitourinary infections (19,20,43,44). Reduced sensitivity and altered distensibility of 
the urinary bladder due to autonomic neuropathy can result in stagnation of urine and 
higher rates of catheterization (45). Moreover, glycosuria can create a favourable 
environment that promotes the growth of bacteria and yeast (e.g. Candida albicans) 
growth (46-48).  Additionally, glycosuria impairs phagocytosis, reducing the ability to 
fight infection (49). People with diabetes may have increased susceptibility to blood 
stream infections for several reasons. Co-existing morbidities, such as microvascular and 
macrovascular complications, neuropathy, and diabetic foot disease play a role as well in 
acquiring blood stream infections. A correlation of head and neck infections was also 
linked to diabetes, where contributing factors involve higher salivary glucose, low 
salivary pH, microangiopathy, and abnormal collagen metabolism (19,20,26,28,50,51).  
The pathogenic link involves diabetes-induced changes in immune cell function causing. 
It was demonstrated in this review that viral infections are linked to diabetes. The 
association between diabetes and viral infections is supported by various diabetes specific 
in vitro defects in innate and adaptive immunity, and studies that showed that long-
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standing diabetes is often accompanied by impaired cell-mediated immunity, which 
increases the risk to more severe and widespread infections. This could also be the case 
for gastrointestinal infections and other types that were shown in the review. 
Although infection was associated with diabetes across all types of infections, there was a 
difference in magnitude of this association between these types of infections. Although 
the reasons for these differences are unclear, there are several potential explanatory 
factors. Certain infections (e.g., Head and Neck, Viral infecitons) had a small number of 
studies limited the power to detect differences in infections. Another factor that might 
play a role in this discrepancy is lack of information on type of diabetes, type of diabetic 
medications, and duration of diabetes which might have affected the outcome.  
It is important to note that most of the studies included in this review were of moderate 
quality according to the risk of bias tool used. Furthermore, in an attempt to test for 
publication bias funnel plots were generated. Most of these plots were asymmetrical (skin 
and soft tissue, respiratory, genitourinary and blood-stream infections). Causes for 
asymmetry in these plots could be due to differences in individual studies included in this 
review; selection bias, true heterogeneity (size of effect differes according to study size, 
intensity of intervention and differences in underlying risk factors), methodological 
differences (poor analysis in smaller studies, inadequate analysis) and chance.   
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2.4.1 Strengths and Limitations: 
To our knowledge, this is the first systematic review and meta-analysis that examines the 
association between diabetes and different types of infection. Strengths of this systematic 
review include a comprehensive search strategy, inclusion of patient important outcomes, 
inclusion of studies with an explicit temporal relationship whereby diabetes preceeded the 
infection, and a rigorous quality assessment of included studies. This review included a 
large number of observational studies with both general and specific populations resulting 
in a broad representation of the population at-risk, and may better reflect better the nature 
and frequency of unintended effects experienced in clinical practice. 
 
Despite these positive aspects, some limitations must be noted here. Observational studies 
are methodologically challenging, difficult to interpret and susceptible to several types of 
bias and confounding, mainly selection bias (referral bias, volunteer bias, loss to follow 
up bias) and information bias (exposure ascertainment bias, outcome ascertainment bias). 
Some epidemiological studies of diabetes have used self-reported assessments of 
prevalent diabetes. Self reported measures of diabetes status have been previously shown 
to be over 99% specific and 66% sensitive compared with medical records (52). In 
addition, misclassification of patients with diabetes who did not know that they had the 
disease to the referent group of participants without diabetes is highly likely given that 
46% of the estimated prevalence of diabetes is in people with undiagnosed disease (1). 
 
Another important limitation to understand is that some studies did not have diabetes 
and/or infection as the primary exposure/outcome. None the less, the required information 
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needed to conduct our analysis was present in these studies. 
The limitation of having a single reviewer assessing the quality of each study should be 
recognized. However, 2 reviewers besides the main reviewer verified data extraction.  
The heterogeneity found in this review was somewhat high. Heterogeneity was explored 
across our results by grouping infections in several subtypes, and further grouping those 
into subcategories. This grouping managed to decrease heterogeneity of our results. 
Finally, only studies in English in the review were included as translation of texts was not 
feasibile. However, our review managed to obtain over 340 studies. Although non-
English studies were not included, others have shown excluding non-English studies 
appeared not to influence the results substantially (53,54). 
 
 
 
2.5 Conclusion 
 
In conclusion, our systematic review and meta-analysis quantified the association 
between diabetes and several types of common infections. The strength and significance 
of the association varied according to the type of infection studied. The knowledge 
generated from this review will help further inform physicians and researchers toward the 
best summary of evidence. However, more research is needed to explore the effects 
patient characteristics such as classificaiton of diabetes, BMI, and glycemic control may 
have on the risk of these types of infections. 
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Table 1: Study Characteristics of Observational Studies Evaluating the Association 
Between Diabetes and Infection  
 
 
CHARACTERISTICS COHORT 
STUDIES 
N=243 
CASE-
CONTROL 
STUDIES 
N=102 
Total N=345 
Year of Study, n(%) 
<1990 
1990-1994 
1995-1999 
2000-2004 
2005-2009 
2010-2014 
 
 
4 (1.6) 
8 (3.3) 
8 (3.3) 
33 (13.6) 
64 (26.3) 
126 (51.8) 
 
 
1 (0.98) 
4 (3.9) 
12 (11.8) 
20 (19.6) 
34 (33.3) 
31 (30.4) 
 
5(1.4) 
12(3.5) 
20(5.8) 
53(15.4) 
98(96.1) 
157(45.5) 
Mean Age (range),  
no. of Studies 
 
61.9 (28-80), 
n=172 
 
 55.9 (26-76), 
n=54 
61 (26-80), 
n=226 
Sex N%, no. of Studies (n) 
Male  
 
 
16,615,301 
(48.2) 
 
763,173  
(52) 
 
17,378,474  
(48.3) 
 52 
Female 
 
17,852,673 
(51.8),  
n=221 
 
703,693  
(48),  
n=82 
18,556,366 
(51.7),  
n=303 
Mean Follow up (yrs),  
no. of Studies 
 
4.4,  
n=70 
N/A 4.4, 
n=70 
Setting, n(%) 
Hospital 
Clinic 
Hospital & Clinic 
Long term facilities 
 
216 (88.9) 
18 (7.4) 
8 (3.3) 
1 (0.4) 
 
85 (83.3) 
11 (10.8) 
5 (4.9) 
1(1) 
 
 
301 (87.2) 
29 (8.4) 
13 (3.8) 
2 (0.6) 
Region, n(%) 
Europe  
Asia 
North America 
South America  
Africa 
 
 
62 (25.5) 
61 (25.1) 
111 (45.7) 
7 (2.9) 
2 (0.8) 
 
38 (37.2) 
18 (17.6) 
44 (43) 
2 (2) 
0 (0) 
 
100 (29) 
79 (22.9) 
155 (44.9) 
9 (2.6) 
2 (0.6) 
Population, n(%) 
General population 
 
71 (29.2) 
 
54 (53) 
 
125 (36.2) 
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Cardiovascular Disease  
Bone Disease  
Kidney Disease  
Malignancy 
Gastrointestinal Disease 
Spine Disease 
Organ Transplant 
Genitourinary Disease 
Critically Ill 
Pregnancy 
Burn 
Ophthalmologic 
Respiratory Disease 
Obesity 
Breast Reconstruction 
Autoimmune Disease 
72 (29.6) 
16 (6.6) 
17 (7) 
14 (5.8) 
10 (4.1) 
10 (4.1) 
7 (2.9) 
8 (3.3) 
4 (1.6) 
4 (1.6) 
3 (1.2) 
0 (0) 
2 (0.8) 
1 (0.4) 
3 (1.2) 
1(0.4) 
 
18 (17.6) 
7 (6.9) 
4 (3.9) 
2 (2) 
3 (2.9) 
2 (2) 
4 (3.9) 
1 (1) 
5 (4.9) 
0 (0) 
0 (0) 
2 (2) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
90 (26.1) 
23 (6.7) 
21 (6.1) 
16 (4.6) 
13 (3.8) 
12 (3.5) 
11 (3.2) 
9 (2.6) 
9 (2.6) 
4 (1.2) 
3 (0.9) 
2 (0.6) 
2 (0.6) 
1 (0.3) 
3 (0.9) 
1 (0.3) 
Outcome, n(%) 
Unspecified Infections 
Skin and Soft Tissue Infections 
Respiratory Tract Infections 
Genitourinary Infections 
 
36 (14.8) 
114 (46.9) 
17 (7) 
18 (7.4) 
 
12 (11.8) 
36 (35.3) 
14 (13.7) 
11 (10.8) 
 
48 (13.9) 
150 (43.5) 
31 (9) 
29 (8.4) 
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Gastrointestinal Infections 
Head & Neck Infections 
Blood Infections 
Viral Infections 
Bone Infections 
Other Infections 
Multiple Infections 
 
1 (0.4) 
1 (0.4) 
16 (6.6) 
7 (2.9) 
2 (0.8) 
1 (0.4) 
30 (12.3) 
6 (5.9) 
2 (2) 
10 (9.8) 
4 (3.9) 
2 (2) 
4 (3.9) 
1 (1) 
7 (2) 
3 (0.9) 
26 (7.5) 
11 (3.2) 
4 (1.2) 
5 (1.4) 
31 (9) 
 
Newcastle-Ottawa Scale 
(NOS), n(%)  
Weak (score 0-3) 
Moderate (score 4-6) 
Strong (score 7-9) 
 
 
 
0 (0) 
197 (81) 
46 (19) 
 
 
0 (0) 
82 (80.4) 
20 (19.6) 
 
 
0 (0) 
279 (80.9) 
66 (19.1) 
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Table 2: Reported Infections in Included Studies 
 
Type of Infection Study Reported Infections 
Skin and Soft 
Tissue 
Surgical site=148 
Unspecified=15 
Peritonitis=7 
Burn=3 
Cellulitis=2 
Erysipelas=2 
Scabies=1  
 
Respiratory Pneumonia=29 
Tuberculosis=19 
Unspecified=5 
 
Genitourinary Urinary=46: 
Unspecified=34 
Bacteruria=3 
Cystitis=3 
Pyelonephritis=3 
Prostatitis=1 
Urethritis=1 
 56 
Renal Abscess=1 
 
Genital=10: 
Unspecified=4 
Balanitis=1 
Vaginitis=2 
Chorioamenionitis=1 
Endometritis=1 
Vaginal Candidiasis=1 
 
Gastrointestinal Clostridium Difficile Associated Diarrhea=3 
Liver Abscess=2 
Diarrhea=1 
Gastroenteritis=1 
Enteric=1 
Salmonellosis=1 
Biliary tree=1 
Unspecified=1 
 
Head and Neck Endophalmitis=3 
Otitis Externa=2 
Otitis Media=1 
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Mastoditis=1 
 
Musculoskeletal Osteomyelitis=5 
Joint=3 
 
Viral Herpes Zoster=8 
Herpes Simplex=2 
Influenza=2 
Hepatitis=2 
Human Papilloma=1 
Human Immunodeficiency Disease=1 
Unspecified=1 
 
Other Zygomycosis=3 
Cardiovascular=2 
Unspecified=2 
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Figure 2 (A): Cohort Studies Crude Results Odds Ratio (OR) by Infection Type:   
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Figure 2 (B): Cohort Studies Adjusted Odds Ratio (OR) Results by Infection Type:   
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Figure 2 (C): Case-Control Studies Crude Odds Ratio (OR) Results by Infection  
Type:   
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Figure 2 (D): Case-Control Studies Adjusted Odds Ratio (OR) Results by Infection  
Type:   
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Table 3: Skin and Soft Tissue Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR  
(95% CI) 
I2 No of 
Studies 
Adjusted OR  
(95% CI) 
I2 
Surgical site 
Infections 
 
Cohort 105 2.09 (1.90-2.31) 91.4% 56 2.02 (1.82-2.24) 86.4% 
 Case-
Control 
30 3.12 (2.37-4.11) 0% 
 
14 2.62 (2.15-3.20) 0% 
General 
Surgery 
Cohort 17 1.66 (1.19-2.31) 94.7% 6 1.65 (1.20–2.28) 72.2% 
 
 Case-
Control 
5 4.28 (1.14-
16.12) 
94.9% 2 2.11 (1.37–3.26) 0% 
 
Cardiovascular 
Surgery 
Cohort 44 2.20 (1.93-2.50) 59.9% 29 2.08 (1.85–2.35) 75.3% 
 
 Case-
Control 
15 2.71 (2.20-3.33) 18.2% 7 2.76 (2.13–3.57) 0% 
 
Orthopedic 
Surgery 
Cohort 16 2.50 (1.90-3.30) 73.0% 8 1.96 (1.16–3.34) 74.9% 
 
 Case-
Control 
4 2.45 (1.66-3.62) 0% 2 2.32 (1.37–3.94) 0% 
 
Spine Surgery Cohort 12 3.03 (1.80-5.12) 87.0% 6 2.14 (1.44–3.18) 25.9% 
 
 Case-
Control 
5 4.24 (2.57-7.00) 0% 3 4.15 (1.99–8.66) I2=0% 
 
Skin Surgery Cohort 3 1.65 (0.88-3.06) 51.3% 3 1.51 (1.07–2.13) 43.3% 
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Maxillo-Facial 
Surgery 
Cohort 2 2.95 (1.28-6.83) 83.6% 2 4.01 (1.69–9.54) 84.0% 
 
Gynecological 
Surgery 
Cohort 2 1.28 (0.32-5.13) 85.4%  no studies 
identified 
 
 
Plastic surgery Cohort 6 1.92 (1.18-3.13) 0% 
 
 no studies 
identified 
 
Ear Nose 
Throat surgery 
Cohort 3 2.07 (0.80-5.38) 48%  no studies 
identified 
 
 
 Case-
Control 
6 2.30 (1.70-3.12) 96.3% 
 
6 1.66 (1.30-2.12) 85.1% 
Other Skin 
and Soft 
Tissue 
Infections 
Cohort 14 2.22 (1.67-2.95) 91.8% 
 
7 1.83 (1.73-1.94) 53% 
 Case-
Control 
4 1.69 (1.05-2.72) 55.8%  no studies 
identified 
 
Peritonitis Cohort 4 3.66 (1.18-
11.36), 
93.3% 
 
2 1.37 (0.95-1.97) 0% 
Erysipelas Case-
Control 
2 1.24 (0.87-1.75) 0% 
 
 no studies 
identified 
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Table 4: Respiratory Tract Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
Upper 
Respiratory 
Tract 
Infections 
 
Cohort  no studies 
identified 
 1 1.18 (1.17-1.19) 0% 
Lower 
Respiratory 
Tract 
Infections 
 
Cohort 30 1.45 (1.32-1.61) 83.4% 14 1.35 (1.28-1.43) 78.7% 
 Case-
Control 
12 2.06 (1.71-2.50) 95.3% 10 1.60 (1.35-1.89) 86.7% 
Tuberculosis Cohort 10 1.35 (1.18-1.56) 84.3% 9 1.31 (1.20–1.42) 60% 
 Case-
Control 
7 2.42 (1.86-3.15) 95.0% 6 1.86 (1.44-2.41) 87.1% 
Pneumonia Cohort 19 1.53 (1.29-1.83) 82.8% 6 1.43 (1.36-1.51) 70.1% 
 Case-
Control 
6 1.61 (1.27-2.04) 78.9% 4 1.26 (1.21-1.31) 0% 
Unspecified 
Respiratory 
Tract 
Infections 
Cohort 2 1.50 (0.56-4.05) 85.7%  no studies 
identified 
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Table 5: Genitourinary Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
Genital 
Infections 
 
Cohort 5 2.06 (1.20-3.52) 84.3% 4 1.41 (1.14-1.74) 98.6% 
Male 
 
Cohort 2 3.47 (2.93-4.11) 0% 2 1.28 (1.01-1.64) 98.8% 
Female 
 
Cohort 3 1.57 (0.60-4.14) 89.6% 3 1.49 (1.17-1.91) 92.6% 
Urinary 
Infections 
 
Cohort 25 2.00 (1.79-2.23) 90.9% 11 1.75 (1.52-2.00) 99.0% 
 
 
Case-
Control 
9 3.06 (2.21-4.23) 81.2% 7 2.59 (1.60-4.17) 86.0% 
Urinary Tract 
Infections 
Cohort 23 1.99 (1.77-2.24) 91.1% 9 1.49 (1.30-1.72) 98.8% 
 Case-
Control 
8 2.98 (2.12-4.19) 82.7% 6 2.45 (1.48-4.05) 87.4% 
Renal 
Infections 
Cohort  no studies 
identified 
 2 2.40 (1.55-3.71) 98.4% 
Bacteriuria Cohort 3 1.94 (1.77-2.13) 
 
0% 2 1.81 (1.66-1.97) 0% 
Unspecified Cohort 2 1.55 (1.11-2.18) 0%  no studies  
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Genitourinary 
Infections 
identified 
  
 
 
Table 6: Blood Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
End Stage 
Renal Disease 
 
Cohort 5 1.14 (0.24-5.44) 99.6% 5 1.71 (1.37-2.13) 80.7% 
Cardiovascula
r Disease 
 
Cohort 7 1.61 (1.46-1.78) 0% 4 1.36 (1.30-1.43) 0% 
Critical Care 
Patients 
Cohort 2 2.16 (1.48-3.17) 
 
0% 2 1.92 (1.35-2.75) 0% 
 Case-
Control 
3 4.10 (2.26-7.43) 0% 2 3.29 (1.42-7.62) 
 
0% 
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Table 7: Viral Infections:  
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
Herpes Zoster 
(shingles) 
 
Cohort 2 1.39 (1.34-1.43) 0% 4 1.42 (1.20-1.69) 97.2% 
 Case-
Control 
 
3 0.96 (0.32-2.90) 99.9%  no studies 
identified 
 
 
 
Table 8: Head and Neck Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
Endophalmitis 
 
Case-
Control 
2 1.55 (0.22-
11.10) 
80.7%  no studies 
identified 
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Table 9: Gastrointestinal Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
Clostridium 
Difficile 
Associated 
Disease 
(CDAD) 
 
Case-
Control 
3 1.66 (0.72-3.86) 86.6%  no studies 
identified 
 
 
 
Table 10: Unspecified Infections: 
 
Subgroup Study 
Design 
No of 
Studies 
Crude OR 
(95% CI) 
I2 No of 
Studies 
Adjusted OR 
(95% CI) 
I2 
Cardiovascula
r Disease 
 
Cohort 15 1.92 (1.50-2.46) 92.6% 7 1.83 (1.40-2.41) 82.5% 
Bone Disease 
 
Cohort 4 1.69 (0.82-3.48) 83.2% 3 1.37 (0.93-2.00) 46.7% 
End Stage 
Renal Disease 
Cohort 2 1.91 (1.35-2.68) 0% 1 1.36 (1.21-1.52) 88.3% 
Organ 
Transplant 
Cohort 2 5.42 (2.10-
14.02) 
66.4%  no studies 
identified 
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 Case-
Control 
 no studies 
identified 
 2 6.90 (3.02-
15.78) 
0% 
Cancer Cohort 4 2.23 (1.23-4.04) 69.2%  no studies 
identified 
 
Critical Care 
Patients 
Case-
Control 
2 2.30 (0.37-
14.23) 
79.2%  no studies 
identified 
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Chapter 3: 
 
Diabetes and the Occurrence of Infection in Primary Care: A 
Matched Cohort Study 
 
 
 
3.1 Introduction 
 
In 2014, the International Diabetes Federation estimated that over 385 million people 
were diagnosed with diabetes globally, and this number is expected to increase to more 
than 595 million people in the year 2035 (1). In Canada, the estimated prevelance of 
people with diabetes was 6.7% of the total population in 2014 (2). By 2019, that number 
is expected to grow to 3.7 million (2). Although diabetes is associated with chronic 
complications of the microvasculature and microvasculature (3) other non-traditional 
complications including connective tissues disorders and impaired immunity are 
becoming increasingly recognized (4).   
 
Infection is a relatively frequent reason for hospitalization or a physician office visit in 
people with diabetes. In fact, 40% of all people with diabetes have at least one physician 
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claim, and nearly 6% have at least one hospitalization for an infectious disease each year 
(5). Moreover, infectious disease contributes to substantial financial costs in people with 
diabetes. A study that was done in North California estimated the proportion of costs 
spent on treating the complications associated with all types of diabetes across different 
age groups (<19->65 years). Costs were categorized into inpatient care, outpatient care 
(primary care, speciality, emergency, non-physician care), pharmacy and out of plan 
refferals and claims. They found that there was almost an excess cost of 5 million dollars 
spent due to infections over one year for people with diabetes compared to people without 
diabetes (6). 
 
People with diabetes may be more susceptible to infectious disease than those without 
diabetes. Immunologic research has demonstrated several defects in host immune defense 
mechanisms in people with diabetes. Phagocytic capabilities of neutrophils are adversely 
affected by hyperglycemia, including impaired migration, phagocytosis, intracellular 
killing, and chemotaxis (7,8). Besides generalized impairments of immunity, 
macrovascular disease and microvascular dysfunction may result in compromised local 
circulation leading to delayed response to infection and impaired wound healing (9). 
Unawareness of lower extremity trauma due to sensory neuropathy may result in 
inadequate attention to minor wounds and subsequent increased infection risk. Incomplete 
bladder emptying due to autonomic neuropathy permits urinary colonization by 
microorganisms, where high glucose concentration in the urine promotes the growth of 
some microorganisms (10).  
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Given the paucity of studies that have explored the relationship between diabetes and the 
susceptibility to different types of infections in a primary care setting (5,11), it was sought 
to conduct a matched cohort study to measure the relationship between diabetes and 
susceptibility to common infections in primary care. 
 
 
 
3.2 Methods 
 
 
3.3.1 Study Design: 
A matched cohort study using the Newfoundland and Labrador (NL)  Canadian Primary 
Care Sentinel Surveillance Network (CPCSSN) database was conducted. 
 
 
3.2.2 Data Source: 
CPCSSN is Canada’s first multi-disease electronic medical record (EMR)-based 
surveillance system (12). Participating community-based primary care clinics across 
Canada contribute information to CPCSSN on five chronic and mental health conditions 
(i.e., diabetes, chronic obstructive pulmonary disease, depression, hypertension, 
osteoarthritis) and three neurological conditions (i.e., alzheimers and related dementias, 
epilepsy, and parkinsons) (13). In NL,  the Atlantic Practice Based Research Network 
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(APBRN) is a group of primary care providers that contribute information to CPCSSN. 
For this study, de-identified data was used from the NL-CPCSSN database. In NL there 
are almost 500 family physicians. Approximately 10% of those physicians contribute data 
to the CPCSSN dataset, representing around 45,000 patients by the end of 2013. 
Information available includes patient demographics (age, sex, socioeconomic status), 
health behaviors (smoking & alcohol intake), physiological data (e.g., blood pressure, 
body mass index) and laboratory data (e.g., cholesterol, HbA1c, fasting glucose, renal 
function), physician diagnoses, prescription medications, and vaccination. The sensitivity 
and specificity of diagnostic algorithms for diabetes in the database was very high with a 
100% and 99%, respectively (14). The CPCSSN database has been used for several 
epidemiologic studies (15-18).  
 
 
3.2.3 Inclusion Criteria: 
All patients who had diabetes and were 18 years and older between January 1, 2008 and 
March 31, 2013 were included. Diabetes was defined using the CPCSSN validated 
algorithm based on International Classification of Disease (ICD-9) billing codes, problem 
lists, medications, and laboratory values (13) (Appendix 3.A). January 1, 2008 or the date 
a person was diagnosed with diabetes after January 1, 2008 was considered a persons 
cohort entry or index date. Controls were randomly selected from patients without 
diabetes that were alive on the date their matched patient with diabetes entered the cohort. 
Up to 8 controls were selected for each patient with diabetes and matched on index year.  
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3.2.4 Exclusion Criteria: 
Patients with a diagnosis of malignancy; HIV infection; organ transplantation; use of 
immunosuppressive medications, ≥ 10 corticosteroids or antibiotics prescriptions in the 
year prior to the study cohort entry date were excluded from the study (11) (See 
Appendix 3.B for diagnostic codes). 
 
 
3.2.5 Outcome Measures: 
The primary outcome was the occurrence of one or more primary care physician visits for 
any infectious disease during follow-up. The CPCSSN dataset use ICD-9 codes for all 
diagnoses (encounter diagnosis, health condition, and family history). CPCSSN does not 
have a limit on ICD9 codes. Infection-related visits to the primary care physician were 
identified using ICD-9 codes, problem lists, and medications (Appendix 3.A). 
Secondary outcomes included the number of head and neck infections, respiratory tract 
infections, gastrointestinal infections, genitourinary tract infections, skin and soft tissue 
infections, musculoskeletal infections and viral infections (See Appendix 3.A for 
diagnostic codes).  
 
Patients were followed from their index date until March 31, 2014. Given multiple 
episodes of infection occurred throughout follow-up, a new episode was defined if a 
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patient was free of signs or symptoms for a 30-day period. A second episode occurring 
>30 days after the initial episode was considered to be a recurrence (Appendix 3.D).  
 
 
3.2.6 Statistical Analysis: 
Baseline characteristics among patients with new or existing diabetes were compared to 
those without diabetes using chi-square tests for categorical variables and t-tests for 
continuous variables. Crude and adjusted OR’s were  measured using univariate and 
multivariable conditional logistic regression analyses to determine if diabetes was 
independently associated with the occurrence of the primary and secondary outcomes. 
Potential confounding variables included in our statistical model were defined based on 
biological rationale, clinical experience, those available within the CPCSSN, and those 
used in other studies evaluating diabetes and infection. Specifically, adjustement was 
done for demographics (age, sex), the presence of comorbidities (microvascular disease 
[nephropathy, neuropathy, retinopathy], macrovascular disease [coronary artery disease, 
peripheral and cerebral vascular disease], heart failure, respiratory disease, dyslipidemia, 
fatty liver disease, and obesity), medications (acid inhibitors, respiratory system 
medications, anti-lipids and vaccines), lab tests, doctor visits, referral to specialists and 
number of infections in the year prior to enrollment in our statistical models (Appendix 
3.D). Testing for presence of a multiplicative interaction was done using the likelihood 
ratio test between diabetes and age, sex, microvascular and macrovascular disease.  
 
To test the robustness of our primary analysis sensitivity analyses was conducted. First, 
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restriction of follow-up period to 1 year was done and repeated the analyses for both the 
primary and secondary outcomes. Second, the analysis was repeated for the primary 
outcome evaluating 1 or more, 2 or more, and 3 or more infections. Third, given the high 
number of infection recurrences throughout follow-up, fixed effects conditional poisson 
regression model was used to quantify the association between diabetes and the number 
of infections, whereby adjusted incidence rate ratios were calculated.  All analyses was 
conducted using Stata 12/MP with a p-value of < 0.05 considered statistically significant. 
 
 
 
3.3 Results 
 
A total of 1,779 patients who had diabetes and 11,066 patients without diabetes were 
followed for an average of 4.2 years. The average age of the total population was 45.1(SD 
16.4) years and the majority were females (59%). Patients with diabetes were on average 
older, underwent more laboratory tests in the year prior to study entry, were more likely 
to receive vaccines, acid-suppressing medications and lipid-lowering medications, and 
were more likely to have existing macrovascular or microvascular disease at study entry 
compared to controls. However, number of infections and recurrences before 1-year entry 
to the study was higher in patients with no diabetes, but both groups were similar with 
regards to number of doctor visits on average (Table 1). Most patients with diabetes were 
treated with metformin constituting 60.5% of the group, while 22% were on insulin.  
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The proportion of patients with diabetes who had one or more primary care visits for an 
infection was similar to patients without diabetes (57% vs. 58%). Proportions were also 
comparable between groups within a 1-year follow-up period (33% vs. 32%) (Table 2). 
The rate of infections per 100 person-years (PYs) was similar between patients with 
diabetes and patients without (42.7 per 100PYs vs. 42.5 per 100PYs) (Table 3). Tables 2 
and 3 display the proportions and rates for specific types of infections. Respiratory tract 
infections were the most common infections reported.  
 
After controlling for potential confounding, patients with diabetes had an increased odds 
of any infection compared to patients without diabetes (adjusted OR=1.21, 95%CI 1.07-
1.37, P value=0.002) (Table 4). There was no significant association between diabetes 
and head and neck infections (adjusted OR=1.10, 95%CI 0.87-1.39, P value=0.428). 
While the risk in patients with diabetes was  increased in respiratory infections (adjusted 
OR=1.31, 95%CI 1.14-1.50, P value=<0.001), gastrointestinal infections (adjusted OR 
=1.41, 95%CI 1.13-1.75, P value=<0.001), genitourinary infections (adjusted OR=1.42, 
95%CI 1.17-1.73, P value=<0.001), and finally skin and soft tissue infections (adjusted 
OR=1.65, 95%CI 1.36-2.01, P value=<0.001). There were no significant differences 
when examining musculoskeletal (adjusted OR=1.05, 95%CI 0.87-1.28, P value=0.606) 
or viral infections (adjusted OR=1.11, 95%CI 0.83-1.47, P value=0.485) 
   
There was a significant interaction between diabetes and age for respiratory infections 
(likelihood ratio test for interaction p=<0.001) and viral infections (likelihood ratio test 
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for interaction p=0.006). A stronger association was shown between diabetes and 
respiratory infections (adjusted OR=1.24, 95%CI 1.08-1.42, P value=0.002) and viral 
infections (adjusted OR=1.48, 95%CI 1.07-2.06, P value=0.018) in patients ≥65; 
however, in patients <65 years there was a weak or no association (Respiratory infection: 
adjusted OR=1.07, 95%CI 0.91-1.25, P value=0.397; adjusted OR=1.15, 95%CI 0.86-
1.53, P value=0.336).  
 
Our findings were consistent when examining the odds of infections over a 1-year period 
(Table 5). Recurrence of any infection was also calculated in the study population for ≥1, 
≥2 and ≥3 infections (Table 6). There was a consistent increase in the odds with number 
of recurrences. The odds of recurrences ≥2 infections was (adjusted OR=1.30, 95%CI 
1.12-1.50, P value=<0.001), and recurrences ≥3 infections was (adjusted OR=1.51, 
95%CI 1.27-1.79, P value=<0.001). In addition, through a fixed effects conditional 
poisson regression model, an increased incidence rate ratio (IRR) of any infection was 
found in patients with diabetes compared to those without diabetes (adjusted IRR=1.25, 
95%CI 1.20-1.31, P value=<0.001). 
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3.4 Discussion 
In the current study patients with diabetes have a 21% increased chance of developing a 
new infection compared to patients without diabetes in primary care practices over 4 
years. The positive association between diabetes and the development of a community-
acquired infection was observed within the first year of follow-up (37% relative odds 
increase). The strongest magnitude of association was found for skin and soft tissue 
infections (65% relative odds ), followed by genitourinary (42% relative odds increase), 
gastrointestinal (41% relative odds increase), and respiratory infections (31% relative 
odds). A consistent, slightly stronger, measure of and association was observed in the one 
year follow up. However, no association was present for head and neck, musculoskeletal 
and viral infections. A gradient response was also present with the number of any 
infection and diabetes. Interestingly, we found that the number of infections and 
recurrences before 1-year entry to the study was higher in patients with no diabetes. 
Higher rates of infection in patients with no diabetes group here is likely due to the fact 
that they are on average younger than patients with diabetes (19).  
 
Very few studies have explored the relationship between diabetes and the occurrence of 
general infections in a primary care setting (5,20-24). When comparing our results with 
other studies that examined this relationship in a primary care setting, they were 
consistent with most who have found increased rates of infections in patients with 
diabetes compared to patients without (5,20-23). For example, Shah and Hux examined 
the association between diabetes and different types of infections using administrative 
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databases from Ontario, Canada (5). They quantified the risk of infections in patients with 
diabetes. Despite the reliance on an administrative dateset and a short study duration (1 
year), the authors found an increased risk of infectious disease in patients with diabetes, 
with an even higher risk ratio of infectious disease related hospitalization. Another cohort 
study done in Japan that examined risk factors for infection concluded that diabetes was 
one of the important risk factors. Using hospital records and community data the authors 
reported more than double the risk of infection in patients with diabetes compared to 
those without (21). The findings of this study may not be generalizable to primary care 
patients as the study population had autoimmune diseases. In addition important 
confounders that may affect the outcome, such as corticosteroid therapy, were not taken 
into consideration.  A case-control study that conceded with our findings found more than 
double the risk of infection in patients with diabetes compared to patients without 
diabetes (22). Shortcomings of this study that should be noted are the small number of the 
study population included, and reliance on self-report of medical history and 
socioeconomic status.  
In contrast, Lipsky et al studied risk factors for acquiring pneumococcal infections in a 
general medical clinic and found that diabetes was not a risk factors for developing 
pneumococcal infections (24). However, some limitations of the study should be noted. 
The authors do state that the study population was not ideal, presumably high risk, 
because they were elderly, from lower socioeconomic strata, and had several chronic 
medical problems. Moreover, because the study team relied on medical records, they may 
have missed cases of pneumococcal infections, and undetectable pneumococcal 
vaccinations  may have occurred due to poor documentation . 
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Results of our secondary outcomes were consistent with other studies that looked at skin 
and soft tissue infections (5,11,25-32) with a magnitude of association ranging from 
[aOR=1.3-3.7], respiratory infections (5,11,29,33-43) [aOR=1.2-4.7], genitourinary 
infections [aOR=1.2-2.8] (5,11,44-50), and gastrointestinal infections (5,25,51) 
[aOR=1.3-1.5]. Despite shortcomings of these studies including non-generalizable 
populations (26,27,33,41,44,46,49,50), self reported symptoms (25,29), presence of 
misclassification bias (33,37,42,45,50) or selection bias (28) or reliance on hospital 
records (5,28-32,39,43), their results were consistent with the findings from this study.  
 
There was no difference in the risk of head and neck, musculoskeletal, and viral 
infections in patients with diabetes and patients without, although few studies did find an 
increased risk of these types of infections (5,11,52-56). This might be due to the fact that 
there were a small number of infections in these categories compared to others above. 
 
 
3.4.1 Strengths and Limitations: 
This study has several limitations. First, patients with diabetes and control patients were 
different at baseline with regards to other risk factor (e.g., disease severity, presence of 
comorbidities, different medications and different dosages) that may have confounded the 
observed association between diabetes and infection. However, to minimize confounding 
adjustement was done for known differences between the comparison groups using 
multivariable analysis. Furthermore any differences in disease severity in patients with 
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diabetes which could not be ascertained due to the missingness of hemoglobuin A1C. 
Second, due to the fact that electronic medical records from routine clinical care were 
used to define the diagnosis of diabetes, the potential for misclassification of the diabetes 
(i.e., exposure) exists. Patients with a true diagnosis of diabetes may have been 
misclassified as not having the disease. Moreover, since over one-third of diabetes is 
undiagnosed in the community (57), the true number of patients with diabetes may have 
been underestimated. Alternatively, misclassification for our outcome, infection, may 
have also occurred. The ability to capture all patients with an infection and assessing 
some types infections occurrence in the general population setting is difficult. Some 
infections, such as viral, genital or other infections, are often treated by self-care, i.e., 
using products available over-the counter, symptomatic treatment, or no treatment at all. 
In addition, medical records from general practice were used to identify the occurrence of 
infections; it is possible that infections encountered in a hospital setting or treated at a 
specialist clinic may not be captured. Thus ascertaining such cases via clinical records 
may underestimate incidence. In addition, information was not available for vital status or 
hospitalizations which could have lead to not capturing patients who had an infection but 
were hospitalized without the knowledge of their primary care physician. Moreover, 
vitals can give a more of a clear picture of occurrence, worsening or improvement of an 
infection. Third, increased physician contact for patients with diabetes or differences in 
misclassification may have resulted in diagnosis bias. Physicians may have focused on 
and followed more closely, or treated patients with diabetes differently simply because of 
the misconception of patients with diabetes are more liable to infections (58). Fourth, 
comparison between different types of diabetes and the association of infection was not 
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investigated here. Type of diabetes is a possible effect modifier that could have affected 
the magnitude of measure of association. However, glycemic impairment is expected to 
be similar despite the different types of diabetes, and this does not seem to affect the 
etiology behind the occurrence of infection. Moreover, several studies that examined 
types of diabetes and infection found consistent results with regards to the presence of 
association (11,59,60). Fifth, although age was adjusted for in the model, residual 
confounding may still be present. Matching by age was impractical due to insufficient 
numbers. Finally  using the CPCSSN dataset, is a rich source of data for primary care 
research, may have limited our generalizability. This dataset only includes physicians 
using electronic medical record, and this may differ from other physicians who do not use 
electronic medical records. Given these potential biases, the directionality depends on the 
type of bias. For example, misclassificaiton bias would direct the association towards the 
null; however, diagnostic bias may have shifted the association away from the null. 
Moreover, the CPCSSN dataset is from electronic medical records for clinical practice 
limiting the control of the researcher over the quality of the data.     
 
Having said that, the study has distinctive strengths. First, a unique cohort of patients with 
diabetes treated in a primary care setting was studied. There seems to be minimal research 
done on the association between diabetes and infection in a primary care setting, Our 
study adds to the sparce literature in primary care setting. Second, the study had sufficient 
power to detect statistically significant associations for our primary outcome. Third, data 
was obtained from the CPCSSN database, which is designed specifically for primary care 
research, captures appropriate study variables and important prognostic markers (e.g., 
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glycemic control, BMI, smoking and blood pressure) that are vital for the study design 
(17). In addition, a validated case definition was used to define diabetes status before 
outcome ascertainment (13), thus avoiding differential detection of undiagnosed diabetes 
in adults. Finally, our study included community-based comparison groups yesinstead of 
hospital-based and adjusted for comorbidities, vaccination status, which introduced 
potential bias in some studies (61-63).  
 
 
 
3.5 Conclusion 
In conclusion, our study supports a significant but weak  association between diabetes and 
certain community-acquired infections including skin and soft tissues, gastrointestinal, 
genitourinary and respiratory infections. The implications of glucose control via 
antidiabetic medications on the risk of these infections remains to be determined. 
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Tables: 
 
Table 1: Baseline Characteristics for 12,845 Patients With and Without Diabetes 
Over 4-year Period: 
Variable Diabetes  
(n=1,779) 
 
Non-Diabetes 
(n=11,066) 
P value 
Age  
Mean (SD) 
Median (IQR) 
 
 
57.5 (15.6) 
59.0 (20) 
 
43.1 (16.5) 
41.0 (26) 
<0.001 
Gender n, (%) 
Male 
Female 
 
 
889 (50.0) 
890 (50.0) 
 
4,435 (40.1) 
6,631 (59.9) 
 
<0.001 
<0.001 
Doctor Visits (Mean, SD) 
 
3.7 (3.9) 3.3 (3.8) 0.015 
Referral To a Specialist, n (%) 
0 
1 
≥2 
 
 
1,568 (88.1) 
133 (7.5) 
78 (4.4) 
 
9,927 (89.7) 
755 (6.8) 
384 (3.5) 
 
0.05 
0.338 
0.064 
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Infection before 1-year entry, n (%) 
0 
1 
≥2 
 
 
1,385 (77.8) 
203 (11.4) 
191 (10.7) 
 
6,261 (56.6) 
1,894 (17.1) 
2,911 (26.3) 
 
<0.001 
<0.001 
<0.001 
Lab Tests before 1-year entry  
(Mean, SD) 
14.5 (46.3) 10.6 (33.2) <0.001 
Vaccines, n (%) 
 
251 (14.1) 1,202 (10.9) <0.001 
Acid-suppressing Medications, n (%) 
 
306 (17.2) 983 (8.9) <0.001 
Respiratory Medications, n (%) 
 
173 (9.72) 1,140 (10.3) 0.482 
Lipid-lowering Medications, n (%) 
 
716 (40.2) 653 (5.9) <0.001 
Microvascular Disease, n (%) 
 
29 (1.6) 23 (0.2) <0.001 
Macrovascular Disease, n (%) 
 
76 (4.3) 111 (1) <0.001 
Heart Failure, n (%) 
 
19 (1.1) 16 (0.1) <0.001 
Fatty Liver, n (%) 10 (0.6) 12 (0.1) <0.001 
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Obesity, n (%) 
 
61 (3.4) 129 (1.2) <0.001 
Respiratory Disease, n (%) 
 
236 (13.3) 2,273 (20.5) <0.001 
Follow-up Time, years (Mean, SD) 
 
4.2 (1.7) 4.2 (1.7) 0.788 
 
 
Table 2: Proportion of New Infections in Patients with and without Diabetes Over 2 
Follow-up Periods: 
 
Infection 
Type 
4-year Follow-up Period 1-year Follow-up period 
 Diabetes  
(n=1,779) 
n (%)  
 
Non Diabetes 
(n=11,066) 
n (%) 
P value Diabetes  
(n=1,779) 
n (%) 
Non 
Diabetes 
(n=11,066) 
n (%) 
P value 
Any Infection 
 
1012 (56.9) 6428 (58.1) 0.354 584 (32.8) 3500 
(31.6) 
 
0.327 
Head & Neck 118 (6.6) 817 (7.4) 0.280 39 (2.2) 
 
298 (2.7) 
 
0.252 
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Respiratory  
 
462 (26.0) 3266 (29.5) 0.002 210 (11.8) 
 
1381 
(12.5) 
 
0.445 
 
Gastrointesti
nal 
 
151 (8.5) 694 (6.3) <0.001 69 (3.9) 
 
245 (2.2) 
 
<0.001 
 
Genitourinar
y 
 
203 (11.4) 1172 (10.6) 0.319 93 (5.2) 
 
438 (4.0) 
 
0.015 
 
Skin & Soft 
Tissue 
 
199 (11.2) 896 (8.1) <0.001 78 (4.4) 
 
269 (2.4) 
 
<0.001 
 
Musculoskele
tal 
 
185 (10.4) 1189 (10.7) 0.692 62 (3.5) 
 
388 (3.5) 
 
1.000 
 
Viral 
 
84 (4.7) 428 (3.9) 0.100 30 (1.7) 
 
130 (1.2) 
 
0.091 
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Table 3: New Infections Per 100 Person-Years in Patients With and Without 
Diabetes Over 2 Follow-up Periods: 
 
Infection Type Full Study Period 
(Mean, SD) 
1 year study period 
(Mean, SD) 
 Diabetes  Non-
Diabetes  
P 
value 
Diabetes  Non-
Diabetes  
P 
value 
Any Infection 42.7 (63.0) 42.5 (59.9) 0.895 
 
54.7 (99.3) 50.2 (94.6) 0.077 
 
Head & Neck 2.1 (11.5) 2.2 (9.7) 0.771 
 
2.6 (18.2) 3.0 (19.5) 0.318 
 
Respiratory 13.4 (36.3) 13.9 (30.0) 0.589 
 
16.2 (52.2) 16.3 (49.7) 0.943 
 
Gastrointestinal 3.4 (15.0) 2.2 (11.1) 
 
0.001 
 
4.9 (27.9) 2.7 (19.4) 0.001 
 
Genitourinary 4.8 (18.0) 4.2 (16.5) 0.148 
 
6.9 (33.1) 
 
4.9 (26.7) 0.016 
 
Skin & Soft 
Tissue 
4.1 (15.3) 2.4 (10.5) <0.001 
 
5.2 (26.3) 
 
2.6 (17.4) <0.001 
 
Musculoskeletal 3.7 (14.4) 3.8 (14.5) 0.789 4.3 (25.1) 
 
4.0 (22.3) 0.617 
 
Viral 1.4 (7.1) 1.1 (6.6) 0.083 1.7 (13.5) 1.2 (11.4) 0.122 
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Table 4: Odds Ratio (OR) Between Diabetes and Infection: Crude and Covariate-
Adjusted  Results: 
 
Type of Infection Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Any Infection  
 
0.96 0.86-1.06 0.399 1.21 1.07-1.37 0.002 
Head & Neck  
 
0.90 0.74-1.11 0.328 1.10 0.87-1.39 0.428 
Respiratory 
 
0.84 0.75-0.94 0.003 1.31 1.14-1.50 <0.001 
Gastrointestinal  
 
1.38 1.15-1.67 <0.001 1.41 1.13-1.75 <0.001 
Genitourinary  
 
1.10 0.94-1.29 0.238 1.42 1.17-1.73 <0.001 
Skin & Soft Tissue  
 
1.43 1.21-1.69 <0.001 1.65 1.36-2.01 <0.001 
Musculoskeletal 
  
0.97 0.82-1.14 0.714 1.05 0.87-1.28 0.606 
Viral 
 
1.21 0.95-1.55 0.115 1.11 0.83-1.47 0.485 
Adjusted for age, sex, comorbidities (microvascular disease [nephropathy, neuropathy, retinopathy], 
macrovascular disease [coronary artery disease, peripheral and cerebral vascular disease], heart failure, 
respiratory disease, dyslipidemia, fatty liver disease, and obesity), medications (acid inhibitors, respiratory 
 102 
system medications, anti-lipids and vaccines), lab tests, doctor visits, referral to specialists and number of 
infections in the year prior to enrollment 
 
 
 
Table 5: Odds Ratio (OR) Between Diabetes and Infection Over 1-Year Period: 
Crude and Covariate-Adjusted Results: 
 
Type of Infection Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Any Infection  
 
1.06 0.95-1.18 0.290 1.37 1.21-1.55 <0.001 
Head & Neck  
 
0.83 0.59-1.17 0.285 1.12 0.75-1.67 0.573 
Respiratory 
 
0.94 0.81-1.10 0.470 1.45 1.21-1.74 <0.001 
Gastrointestinal  
 
1.78 1.36-2.34 <0.001 1.71 1.22-2.39 0.002 
Genitourinary  
 
1.34 1.06-1.69 0.248 1.86 1.39-2.50 <0.001 
Skin & Soft Tissue  
 
1.81 1.40-2.34 <0.001 1.96 1.43-2.69 <0.001 
Musculoskeletal  1.01 0.77-1.33 0.915 1.06 0.77-1.47 0.714 
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Viral 
 
1.42 0.95-2.13 0.086 1.33 0.80-2.21 0.268 
Adjusted for age, sex, comorbidities (microvascular disease [nephropathy, neuropathy, retinopathy], 
macrovascular disease [coronary artery disease, peripheral and cerebral vascular disease], heart failure, 
respiratory disease, dyslipidemia, fatty liver disease, and obesity), medications (acid inhibitors, respiratory 
system medications, anti-lipids and vaccines), lab tests, doctor visits, referral to specialists and number of 
infections in the year prior to enrollment 
 
 
 
 
Table 6: Odds Ratio (OR) Between Diabetes and Any Infection Recurrence: Crude 
and Covariate-Adjusted Results: 
 
Recurrences Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
≥1 Infection 0.96 0.86-1.06 0.399 1.21 1.07-1.37 0.002 
≥2 Infection 0.92 0.82-1.04 0.196 1.30 1.12-1.50 <0.001 
≥3 Infection 0.99 0.86-1.13 0.872 1.51 1.27-1.79 <0.001 
Adjusted for age, sex, comorbidities (microvascular disease [nephropathy, neuropathy, retinopathy], 
macrovascular disease [coronary artery disease, peripheral and cerebral vascular disease], heart failure, 
respiratory disease, dyslipidemia, fatty liver disease, and obesity), medications (acid inhibitors, respiratory 
system medications, anti-lipids and vaccines), lab tests, doctor visits, referral to specialists and number of 
infections in the year prior to enrollment 
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Chapter 4 
 
Summary 
 
 
A popular notion among healthcare professionals is that patients with diabetes are more 
liable to developing infections. This view however, lacked the support of necessary 
substantive evidence. The magnitude and precession of the association between diabetes 
and infection was not established in the current literature. To address this gap, especially 
with certain types of infections, two complementary epidemiological studies were 
designed and presented in this thesis. The first study was a quantitative systematic review 
and meta-analyses, while the second study was a matched cohort study.  
 
The first study (chapter 2) aimed to summarize and quantify the association between 
diabetes and infection through a systematic review and meta-analysis. An increased risk 
of numerous types of common infections in patients with diabetes was found; however, 
there existed much variation in results between studies. The results were most compelling 
for skin and soft tissue infections, genitourinary infections, and blood stream infections 
which had the strongest associations following a meta-analysis of studies with a similar 
design. The second study, the matched cohort study, aimed to estimate the association 
between diabetes and infection in a primary care setting. This study resulted in a small 
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increased risk in any infection in patients with diabetes compared to patients without 
diabetes. The highest increase in risk was seen in skin and soft tissue infections. An 
smaller but significant increased risk was also apparent in genitourinary, gastrointestinal, 
and respiratory infections.  
 
These two studies complement each other: the systematic review summarized the current 
knowledge on the association of diabetes and infections from the literature that 
culminated in a meta-analysis, the second study, a matched cohort study examine this 
relationship in a primary care setting where most patients with diabetes are most often 
seen . Both of these studies add to the current evidence-based medicine literature.  
 
 
4.1 Bradford Hill Considerations: 
It is important in epidemiology to separate casual relationships between exposure and 
outcome from non-causal relationships. If a set of necessary casual criteria could be used 
to differentiate between causal and non-causal relationships, the presented research work 
would be solidified. A commonly set of criteria proposed by Sir Austin Bradford Hill was 
first described in 1965 to the Section of Occupational Medicine of the Royal Society of 
Medicine (1). Hill’s lecture had a huge impact on epidemiologists and medical 
researchers. The list of casual criteria was considered a roadmap for researchers (2-4). 
Hill provided nine considerations to distinguish a casual relationship from a non-casual 
one as follows; strength, consistency, specificity, temporality, biological gradient, 
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plausibility, coherence, experimental evidence and analogy. These considerations were 
influenced by others before him (5,6). Hill’s criteria as it is specifically related to this 
thesis will be reviewed here.  
 
Strength of an association is shown through a quantitative measure of effect (e.g, 
relative risk, odds ratio, hazard ratio, absolute risk difference). Hill’s argument is that 
strong associations are more likely to be casual than weak associations. According to 
Monson (7) a measure of association >1.5 is considered moderate to strong. In our cohort 
study, a weak association between the primary outcome, any infection, and diabetes was 
found(odds ratio (OR)= 1.21, 95%CI 1.07-1.37). When examining secondary outcomes of 
the study, only skin and soft tissue infections had a strong association (OR=1.65, 95%CI 
1.36-2.01), while weak associations were present for genitourinary (OR=1.42, 95%CI 
1.17-1.73), gastrointestinal (OR=1.41, 95%CI 1.13-1.75), and respiratory (OR=1.31, 
95%CI 1.14-1.50). Our systematic review and meta-analysis showed strong associations 
with regards to secondary outcomes. Cohort studies revealed skin and soft tissue 
infections (OR=1.95, 95%CI 1.78-2.13, I2=92.8%), blood stream (OR=1.73, 95%CI 1.49-
2.01, I2=94.2%), genitourinary (OR=1.61, 95%CI 1.42-1.83, I2=99.2%) and unspecified 
infections (OR=1.81, 95%CI 1.64-2.00, I2=99.6%) had strong associations. Case-control 
studies showed that skin (OR=2.61, 95%CI 2.17-3.13, I2=0%), respiratory (OR=1.62, 
95%CI 1.37-1.92, I2=85.9%), blood (OR=2.40, 95%CI 1.68-3.42, I2=71.7%), 
genitourinary (OR=2.42, 95%CI 1.61-3.65, I2=83.7%), gastrointestinal (OR=3.61, 95%CI 
2.94-4.43, I2=0%), and non-specific (OR=3.81, 95%CI 2.88-5.04, I2=0%) had strong 
associations.  
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With regards to consistency of results, our cohort study coincides with other studies 
looking at the association of diabetes and infections.  In addition to our cohort study, 
other observational studies examining the association between infections in the 
community and diabetes found the same conclusion with the measure of association 
ranging from [1.21-2.5] (8-12). In contrast, not all studies showed positive associations. 
Lipsky et al showed that diabetes was not considered a risk factor for pneumococcal 
infections. As for secondary outcomes, there was also consistency with the literature (13). 
The risk of skin and soft tissue was also increased in patients with diabetes with odds 
ratio ranging from 1.7-6.2 (10,14-18) among several other studies (19-22). Genitourinary 
infections was also shown to be increased in patients with diabetes in other studies 
(10,20,19-22). Numerous studies concluded positive association with respiratory infection 
and diabetes (10,19,20). Few studies coincided with our results in gastrointestinal 
infections (10,19,38). 
To our knowledge, there is no systematic review that examined the association of all 
types of infections and diabetes. Jeon and Murray (39) conducted a systematic review and 
meta-analysis that looked at tuberculosis and diabetes. They concluded a positive 
association, as found in the systematic review and metat-analysis, in respiratory infection, 
with diabetes with cohort studies having a relative risk (RR=3.1, 95%CI 2.27-4.26) and 
case-control studies ranging from 1.16-7.83. Another systematic review done by Baker et 
al (40) examined the impact of diabetes on tuberculosis treatment. They concluded that 
diabetes increases the risk of relapse of tuberculosis. A narrative review done by Peleg et 
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al (41) studied common infections in diabetes. They concluded that diabetes is a risk 
factor for skin, respiratory and urinary infections.   
 
With temporality, another consideration of Hill, the necessity for a cause to precede an 
effect in time is required for a casual relationship. Temporality can be applied in our case, 
where the occurrence of diabetes precedes the incidence of infection. However, due to the 
retrospective design of the studies included in the systematic review, temporality may not 
be ascertained completely. 
 
Biological plausibility can be applied to the explanation of the observed association 
through known biological mechanisms. Defects in the immune system in patients with 
diabetes; decreased neutrophil capabilities, phagocytosis, chemotaxis, impaired migration 
(42,43), might have a role in the increased incidence of infection compared to patients 
without. Moreover, anatomically specific impairment could be considered another 
mechanism to add on the plausibility. Cardiovascular, neurological complications (44,45) 
and impaired lung function (46,47) increases risk of infections. Bradford Hill considers 
coherence if a cause and effect interpretation of association is clear when it does not 
conflict with what is known about the disease. In other words, the association is coherent 
with the current knowledge as is shown in the association studied here. 
 
Biological gradient may also apply to association at hand. Although this thesis did not 
examine the association between glycemic control and infections, but a dose-response 
relationship is suggested by other literature. This suggests that the severity of diabetes, 
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reflected in poor glycemic control (hyperglycemia and increase in A1C), can be linked to 
the occurrence of infection (48). Animal studies showed that hyperglycemia can worsen 
immune function (49,50). In vitro studies in diabetic patients showed that diabetic cells, 
in comparison with controlled ones, had a reduced cellular immune function(51,52). 
Others have strengthened this theory through several observational studies (53-56). 
 
In addition, experimental evidence (as interpreted by Bradford Hill) supports the 
association between diabetes and infections. People with diabetes have shown some 
evidence of histopathological changes that can give supplementary rationale to the 
present association between diabetes and infection. Diabetes can affect healing (57,58), 
and hyperglycaemia affects coagulation and fibrinolytic function (59), lipid metabolism 
and endothelial function (60,61). Impaired lung functions in these patients contribute to 
acquiring this type of infection as well (62,63). The pathophysiology of lung 
abnormalities in patients who have diabetes is believed to involve microangiopathic 
changes in the basement membrane of pulmonary blood vessels and respiratory 
epithelium, as well as non-enzymatic glycosylation of tissue protein (64-67). 
 
The remaining Bradford Hill criteria including specificity and analogy, do not apply to 
the association studied here. 
 
As discussed above, by reviewing Bradford Hill considerations, there is convincing 
evidence of casual relationship between diabetes and infection. However, while there 
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remains some controversy in the literature, more research is needed to strengthen the 
causal relationship between diabetes and infection. 
 
4.2 Research and Clinical Implications: 
Diabetes is a major public health issue and furthering our understanding of the risk of 
infection among patients living with diabetes has the potential to improve population 
health. The knowledge generated from this review will help further inform physicians and 
researchers and aid in a better understanding of the relationship between diabetes and the 
risk of infection.  The implications of this  research will impact health policy, clinical 
practice and epidemiological research. 
 
 
4.2.1 Health Services:  
The international diabetes federation reported in 2015 almost 415 million people were 
liing with diabetes. In 2040, number of patients living with diabetes is expected to 
increase to over than 640 million people. The cost of management these patients will 
affect the healthcare system expidenture. Health care expenses for people with diabetes is 
estimated to be generally 2-3 fold higher than for patients with no diabetes (68). This 
burden will be reflected in increase doctor visits, follow-up, management and hospital 
admissions. The results of both studies may influence health services policies by 
informing decision makers and those involved in developing clinical practice guidelines. 
Our findings regarding the link between diabetes and infection may impact policies in 
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institutions such as hospitals and nursing homes.  In short, the results of this work will 
support evidence informed policy.  
 
4.2.2 Clinical Practice:  
Our findings can bridge to clinical practice as current clinical behavior, or current 
assumptions by clinicians regarding diabetes and infection, are supported by little 
evidence. As shown in the results the systematic review and cohort study in this thesis, 
patients with diabetes are more liable to certain types of infections compared to patients 
without diabetes. Hence, the study results may enhance evidence-based decision making 
at the point of care by healthcare professionals when treating patients with diabetes, 
especially with regard to decisions that may affect the immune system. This might be 
taken into consideration when managing infections in patients with diabetes with reagrds 
to choice of treatment, dosage, duration and follow-up. 
 
 
4.2.3 Research: 
As shown in the systematic review and meta-analysis and the cohort study done in this 
thesis, there is a relationship between diabetes and infection. However, some research 
needs to be done to focus on some points. Important questions to address in future 
research: 
 Are patients with diabetes with uncontrolled blood sugar more liable to infection 
than patients with diabetes with controlled blood sugar?  
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 Is there any difference in the incidence of infection according to the type of 
diabetes? 
 Do specific anti-diabeteic medications have a role in the occurrence of infections 
in patients with diabetes?  
 What role do certain patient’s characteristics (e.g, body mass index, diabetes 
complications, smoking, etc.) have in patients with diabetes in the occurrence of 
infections? 
 
 
4.3 Conclusion: 
The current thesis presents the results of  two observational studies that examined the 
association between diabetes and the incidence of infection. The first study was a 
systematic review and meta-analysis used to summarize and quantify the association 
between diabetes and infection in the existing literature. This study concluded that 
diabetes is associated with an increased risk of infection. The association was present 
across all types of infections with skin soft tissue, genitourinary and blood infections 
having the strongest associations. The second study was a matched cohort study using a 
provincial dataset, to estimate the association between diabetes and infection in primary 
care. The study found that patients with diabetes have a small increase in risk of any 
infection compared to patients without diabetes. The highest risk was seen with skin and 
soft tissue infections, followed by genitourinary, gastrointestinal and respiratory 
infections. 
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Appendices: 
 
 
Appendix 2.A: Search Strategy 
 
Diabetes and The Occurrence of Infection: Search Strategy 
 
 
 
Information source: 
We searched the following biomedical databases: PubMed, EMBASE, The Cochrane 
Library via Wiley, International Pharmaceutical Abstracts via EBSCO, and Web of 
Science. There was no language restrictions. 
 
Search: 
MeSH and free-text terms were used to search PubMed.  EMTREE and free-text terms 
were used to search EMBASE. The remaining databases were searched using free-text 
terms. 
 
 
PubMed: 
We conducted a MeSH term search (exploded) as well as a free-text search to allow 
identification of articles that have not been indexed with MeSH terms.  
 125 
 
MeSH: 
1. Diabetes mellitus [MeSH terms] 
2. Infections [MeSH terms] 
3. Cohort studies [MeSH terms] 
4. Case-control studies [MeSH terms] 
5. Retrospective studies [MeSH terms] 
6. Observational study [Publication Type] [MeSH terms] 
7. #1 AND #2 
8. #3 OR #4 OR #5 OR #6  
9. #7 AND #8 
 
 
Free-Term Search (title and abstract):  
1.  Diabetes[Title/Abstract] 
2. “Diabetes mellitus”[Title/Abstract] 
3. Infection*[Title/Abstract] 
4. Cohort[Title/Abstract]   
5. Case-control[Title/Abstract]  
6. Retrospective[Title/Abstract]   
7. Observational[Title/Abstract]   
8. #1 OR #2 
9. #3 AND #8 
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10.  #4 OR #5 OR #6 OR #7  
11. #9 AND #10 
 
#9 OR #11 
 
EMBASE: 
We conducted an EMTREE term (exploded) search as well as a free-text search to allow 
identification of articles that have not been indexed with EMTREE terms. 
 
EMTREE: 
1. ‘Diabetes mellitus’/exp 
2. ‘Infection’/exp 
3. ‘Cohort analysis’/exp 
4. ‘Case control study’/exp 
5. ‘Retrospective study’/exp 
6. ‘Observational study’/exp 
7. #1 AND #2 
8. #3 OR #4 OR #5 OR #6  
9. #7 AND #8 
 
 
 
Free text search (title, abstract, keyword): 
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1. Diabetes:ti,ab,de  
2. ‘Diabetes mellitus’:ti,ab,de 
3. Infection:ti,ab,de 
4. Cohort:ti,ab,de  
5. ‘Case-control’:ti,ab,de  
6. Retrospective$:ti,ab,de 
7. Observational: ti,ab,de 
8. #1 OR #2 
9. #8 AND #3 
10.  #4 OR #5 OR #6 OR #7  
11.  #9 AND #10 
 
#9 OR #11 
 
 
The Cochrane Library: 
Databases in the Cochrane Library include: Cochrane Central Register of Controlled 
Trials (clinical trials), Cochrane Database of Systematic Reviews (Cochrane reviews), 
Database of Abstracts of Reviews of Effects (systematic review quality assessments), 
Cochrane Methodology Register (control trial methods), Health Technology Assessment 
Database (technology assessments), NHS Economic Evaluation Database (economic 
evaluations), About The Cochrane Collaboration (Cochrane groups). 
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We conducted free-text searches. Results are limited to Cochrane Reviews (ALL) and 
Other Reviews. 
 
 
Free term search (title, abstract, keyword): 
1. Diabetes 
2. “Diabetes mellitus” 
3. Infection 
4. Cohort 
5. “Case-control” 
6. Retrospective 
7. Observational 
8. #1 OR #2 
9. #3 AND #8 
10. #4 OR #5 OR #6 OR #7 
11. #9 AND #10 
 
 
 
International Pharmaceutical Science:  
We searched using free-text with the “all text” scope. 
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1. Diabetes 
2. “Diabetes mellitus” 
3. Infection* 
4. Cohort 
5. “Case-control” 
6. Retrospective 
7. Observational 
8. S1 OR S2 
9. S3 AND S8 
10. S4 OR S5 OR S6 OR S7 
11. S9 AND S10 
 
 
 
Web of Science: 
We searched using free-terms in this database. 
 
 
1. topic=Diabetes 
2. topic= “Diabetes mellitus” 
3. topic=Infection* 
4. topic=Cohort 
5. topic=“case-control” 
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6. topic=Retrospective 
7. topic=Observational 
8. #1 OR #2 
9. #3 AND #8 
10. #4 OR #5 OR #6 OR #7 
11. #9 AND #10 
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Appendix 2.B: Individual Study Characteristics 
         
Author Year Design Patients 
(n) 
Male 
(%) 
Age, Mean 
(SD) 
Diabetes 
Type 
Outcome NOS 
Score 
         
         
Abbott 2001 Cohort 327993 52.2 63.2 (14.9) unclear Blood 6 
Abdel-Fattah 2008 Case-Control 844 53.8 41.2 (29.4) unclear RTI 6 
Acosta 2012 Case-Control 515 0 30.6 (4.7) 1 Blood   5 
Acosta 2013 Cohort 1622474 0 − 1, 2, 
gestational 
Blood 6 
Adams 2013 Cohort 40491 37.2 − 1, 2 SSTI 6 
Al-Asmary 2004 Case-Control 824 52.7 40.8 (29.6) unclear GU 6 
Alisjahbana 2006 Case-Control 1010 52.5 − unclear RTI 7 
Almirall 1999 Case-Control 680 − − unclear RTI 7 
Álvarez-Lerma 2003 Cohort 1765 66.7 61.2 (15.7) insulin-
treated 
GU 6 
Antonelli 2005 Case-Control 866 31.8 60.8 (12.6) 2 Viral 7 
Apisarnthanar
ak 
2003 Case-Control 60 46.7 − unclear SSTI 6 
Apisarnthanar
ak 
2007 Case-Control 230 30.9 − unclear Unspecifie
d 
6 
Aragón-
Sánchez 
2010 Cohort 283 63.6 − unclear SSTI 6 
Ariyaratnam 2010 Cohort 7420 79.2 − unclear SSTI 6 
Ata 2010 Cohort 1060 − − unclear SSTI 6 
Baaten 2010 Cohort 304 45.4 − unclear Multiple 6 
Bachoura 2011 Case-Control 1783 49.5 − unclear SSTI 5 
Baillot 2010 Cohort 23499 70.7 63.8 (11.4) unclear SSTI 6 
SA 2011 Cohort 500 59 62.1 (9.9) unclear SSTI 5 
Bartholomeeus
en 
2007 Nested Case-
Control 
160000 − − unclear SSTI 5 
Bassetti 2012 Case-Control 495 58.2 61.8 (17.1) unclear Blood   5 
Bedanova 2009 Cohort 150 82.7 54.1 (7) unclear Multiple 6 
Bical 2004 Cohort 712 91 59.6 (9.3) 1, 2 SSTI 6 
Bitkover 1998 Case-Control 111 − 64.2 (11.6) unclear SSTI 6 
Borer 2012 Case-Control 464 70 − unclear Unspecifie
d 
6 
Borger 1998 Cohort 12267 72.2 − unclear SSTI 6 
Bower 2008 Case-Control 63 60.3 61 (10.6) unclear SSTI 5 
Boyko 2005 Cohort 1017 0 − 1, 2 GU 6 
Boyko 2002 Case-Control 1814 0 66.1 (6.2) 1, 2 GU 7 
Bundy 2006 Cohort 3878 75.3 − 1, 2 SSTI 6 
Caire 2011 Cohort 23 100 − unclear SSTI 5 
Carson 2002 Cohort 146786 70.8 65 (3.7) unclear Multiple 6 
Carton 1992 Cohort 101392 − 64.5 (14.4)) 1, 2 Blood 7 
Chen 2012 Cohort 109038 50.4 − 1, 2 GU 7 
Chen L. 2011 Cohort 233 54.9 76.9 (10.5) unclear RTI 6 
Chen S 2009 Cohort 195 − − unclear SSTI 6 
Choudry 2006 Cohort 1027 73 33.5 (11.7) unclear RTI 5 
Chouw 2005 Cohort 246 54.1 51 (13) unclear SSTI 5 
Dalrymple 2010 Cohort 119858 90.5 75.2 (6.5) unclear Unspecifie
d 
7 
Daneman 2010 Cohort 587327 37.8 − unclear SSTI 6 
Davis 2005 Cohort 120 50 64.3 (9.9) 2 Unspecifie
d 
8 
de Souza 2007 Cohort 55 60 45.6 (10.4) unclear Unspecifie 6 
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d 
Boer 2006 Case-Control 521 73.3 56 unclear RTI 7 
Deng 2004 Cohort 751 84.3 56 2 SSTI 6 
Di Palo 1988 Cohort 3796 − − unclear SSTI 5 
Dixon 2009 Cohort 7224 − 65 (16.5) unclear SSTI 5 
Dobler 2012 Cohort 19855283 49.3 − 1,2, 
gestational 
RTI 7 
Dupuy 1999 Case-Control 423 52.3 56.6 (1.3) unclear SSTI 5 
Edmonston 2010 Case-Control 409 50.6 46.3 unclear SSTI 6 
Ennker 2009 Case-Control 3675 − − unclear SSTI 5 
Everhart 2013 Cohort 1875 − − unclear SSTI 6 
Factor 2003 Case-Control 450 − − unclear Unspecifie
d 
6 
Fakih 2007 Cohort 3578 32.5 67.2 (11) unclear SSTI 6 
Farrow 2008 Cohort 105 98 55.2 unclear SSTI 6 
Fernandez-
Sabe 
2009 Case-Control 90 65.5 − unclear Other 6 
Filsoufi 2009 Cohort 5798 37.6 64 (14) unclear SSTI 6 
Floros 2011 Cohort 5649 − 64.5 unclear SSTI 7 
Flynn 2000 Cohort 98 67.3 − 2 SSTI 5 
Friedman 2007 Case-Control 123 65 51.7 (14.5) unclear SSTI 6 
George 2011 Cohort 556 58.1 57.7 unclear SSTI 6 
Gorter 2010 Cohort 6958 0 51 (17) 1, 2 GU 6 
Goswami 2000 Cohort 166 0 31.5 (10.9) 1, 2 GU 6 
Graf 2009 Case-Control 240 68.7 68 unclear SSTI 5 
Gude 2006 Case-Control 489 68 67 (11) unclear SSTI 6 
Guvener 2002 Cohort 1090 70.8 59.6 (10.3) unclear Multiple 6 
Hamilton 2013 Cohort 1139 − 64.1 (11.3) 2 Multiple 7 
Heal 2006 Cohort 857 52.4 56.3 (16.5) unclear SSTI  6 
Heal 2012 Cohort 953 54.3 59.3 (33) unclear SSTI 6 
Herce 2013 Case-Control 105 60 73.3 (11) unclear SSTI 6 
Iorio 2012 Cohort 4241 − − unclear SSTI 6 
Kadija 2011 Cohort 538 0 50 (14) unclear SSTI 6 
Kanafani 2006 Nested Case-
Control 
81 54.3 51 unclear SSTI 5 
Kato 2013 Cohort 981 0 46.4 unclear SSTI 6 
Lai 2007 Case-Control − − − unclear SSTI 6 
Latham 2001 Case-Control 1044 68.6 63.7 (10.3) unclear SSTI 6 
Ledur 2011 Cohort 717 67.4 61.9 (11) unclear Unspecifie
d 
5 
Lee F. 2013 Nested Case-
Control 
66 40.9 − unclear SSTI 6 
Li GQ 2013 Cohort 2061 50.5 51 (16.7) unclear SSTI  6 
Marschall 2007 Case-Control 76 63.1 62.2 (16.3) unclear SSTI 5 
Matsuda 2009 Cohort 11 68.7 61.8 (11.5) unclear SSTI 6 
Mossad 1997 Case-Control 46 71.7 − unclear SSTI 5 
Munoz 2008 Cohort 357 60.2 64.3 (12.7) unclear SSTI 6 
Nakano 2008 Cohort 1500 72.7 67.8 (9.3) unclear SSTI   6 
Schimmel 2010 Nested Case-
Control 
171 42.7 48.6 (15.1) 1, 2 SSTI 6 
Simsek Yavuz 2008 Cohort 991 71.9 56.9 (13.1) unclear SSTI 5 
Singh 1993 Cohort 701 87.9 58.5 unclear SSTI 5 
Siracuse 2013 Cohort 478 57.9 69 unclear SSTI   5 
Spelman 2000 Cohort 690 73.7 − unclear Multiple 5 
Takoudes 2004 Cohort 728 0 29.7 1, 2 Multiple 6 
Talbot 2004 Case-Control 152 − − unclear SSTI 6 
Trinh 2009 Case-Control 202 39.1 58.4 (16.4) unclear SSTI 6 
Veeravagu 2009 Cohort 24774 94.8 − unclear SSTI 5 
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Vilar-Compte 2000 Case-Control 3372 − 50 (17.1) unclear SSTI 6 
Wasson 2013 Case-Control 388 89.7 61.5 unclear SSTI 7 
Wukich 2011 Cohort 1462 39.5 48.2 (15.8) unclear SSTI 5 
Zacharias 1996 Cohort 2317 69.1 62 (10.9) unclear SSTI   6 
John 2001 Cohort 171 64.9 53.5 (6.8) 1, 2 Unspecifie
d 
6 
Hata 2011 Cohort 55492 46.8 60.1 (16.5) unclear Viral 7 
Heymann 2008 Nested Case-
Control 
111189 44.4 − unclear Viral 6 
Muller 2005 Cohort 26328 41.1 63.5 (13.4) 1, 2 Multiple 7 
Hirji 2012 Cohort 271840 53.9 62.6 (13.5) 2 GU 8 
Hirji 2012 Cohort 271840 53.9 62.6 (13.6) 2 GU 8 
Holley 1991 Cohort 60 66.7 48.5 (15) unclear SSTI  6 
Hoy 1985 Cohort 268 59.7 − unclear GU 5 
Hu 2014 Cohort 20655 52.2 − unclear RTI 6 
Hu 2004 Case-Control 1810 0 66.2 (6.3) unclear GU 6 
Ikegami 2012 Cohort 346 48 51.5 (11.8) unclear RTI 6 
Jackson 1995 Case-Control 864 50.5 − unclear Unspecifie
d 
6 
Jackson 2004 Cohort 1017 0 − 1, 2 GU 6 
Kaandorp 1995 Case-Control 4907 30.6 − unclear Other 6 
Kaiserman 2005 Cohort 159634 46.2 65.7 (0.05) unclear Viral 6 
Kang 2012 Cohort 93931 − − unclear GU 5 
Karamanos 2013 Cohort 81165 42 52.5 (13.8) unclear Multiple 6 
Ko 2011 Cohort 1000887 46.9 61 (12.6) unclear GU 8 
Kontoyiannis 2005 Case-Control 81 51.9 51.3 unclear Other 6 
Kornum 2008 Case-Control 376629 52.9 − 1, 2 RTI 6 
Kuo 2013 Cohort 253349 51.1 55.4 (8.8) 2 RTI 8 
Lau 2014 Cohort 166715 52.6 − unclear Viral 8 
Lee CH 2013 Cohort 70782 83 54.5 (22.9) unclear RTI 7 
Lee JH 2013 Case-Control 162 69.7 − unclear GU 5 
Lee MC 2013 Cohort 99806 52.5 61.9 (14.2) 1, 2 TB 7 
Leegaard 2011 Case-Control 17224 53.3 − 1, 2 RTI 6 
Lehmann 2000 Case-Control 92 57.6 − unclear H&N 5 
Leth 2011 Cohort 2492 0 32.1 (4.7) 1,2, 
gestational 
Unspecifie
d 
6 
Leung 2008 Cohort 42116 34.7 72.6 unclear RTI 6 
Lipsky 1986 Case-Control 193 − − unclear Unspecifie
d 
7 
Lui S.A 2007 Cohort 994 93.1 51.5 (11.7) unclear SSTI   5 
Lola 2011 Cohort 172 77.3 66 (10) unclear Unspecifie
d 
6 
Ma  2012 Cohort 376 48.7 73.1 (3.4) unclear SSTI   6 
McKane 2014 Cohort 2551 57.1 65.4 (16) unclear Blood 7 
Michalia 2009 Cohort 343 71.7 52 (17.4) 1, 2 Blood 6 
Monaghan 2011 Case-Control 5736 62.1 51.8 (22.2) unclear GU 4 
Montague 2001 Cohort 491 100 − unclear SSTI 5 
Montan 1998 Case-Control 277 30.7 74.7 unclear H&N 6 
Myers 2012 Cohort 148 41.9 57.3 (10) 1, 2 Unspecifie
d 
6 
Nassaji-
Zavareh 
2007 Cohort 300 48.3 51.8 (22.5) unclear Other 6 
Neal 1997 Case-Control 825 39.5 44.2 (17.3) unclear GI 5 
Halleberg 
Neyman 
2011 Cohort 86 29.1 80 (11.1) unclear GU 6 
Platt 1986 Cohort 1478 51.1 − unclear GU 5 
Partikaki 2008 Cohort 561 67.4 55.5 (18.7) unclear Blood 6 
Ryan 1997 Case-Control 111 − − unclear Blood 5 
Scholes 2005 Case-Control 788 0 32.9 (9.8) unclear GU 6 
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Sheiner 2009 Cohort 199093 0 28.5 (6) gestational, 
other 
GU 6 
Singh 2009 Case-Control 100 − − unclear Other 5 
Strom 2000 Case-Control 546 61.9 − unclear Other 6 
Suputtamongk
ol 
1999 Case-Control 580 59.1 51.5 (15.5) unclear Blood 6 
Terpenning 2001 Case-Control 358 − − unclear RTI 6 
Thomsen 2005 Case-Control 14487 − − 1, 2 Blood 7 
Thomse 2007 Case-Control 73780 54.2 − 1, 2 GI 7 
Thomsen 2011 Case-Control 4357 49.1 − 1, 2 Blood   7 
Toure 2013 Cohort 390 60.5 − 1, 2 Blood 5 
Vidal 2012 Cohort 4388 66.1 50.1 (14.5) unclear GU 6 
Viglino 1994 Cohort 1990 55.9 58 (14.5) unclear Multiple 6 
Wang H.E 2012 Cohort 30183 44.8 − unclear Blood 6 
Wilson 1998 Cohort 389 100 − unclear SSTI 5 
Yang C.H 2012 Cohort 886 74.5 45.2 unclear Unspecifie
d 
5 
Simsir 2010 Cohort 2027 100 64.3 (10.1) unclear Blood 5 
Antonio 2010 Cohort 114 65.8 53.1 (11.7) unclear Unspecifie
d 
5 
Antoniou 2014 Cohort 989302 64.4 − unclear Viral   7 
Blumentals 2012 Cohort 1074315 47.8 − 2 Viral 7 
Clech 2007 Nested Case-
Control 
3281 60.7 − unclear GU 5 
Gajewska 2005 Cohort 45 0 − unclear Viral   6 
Heilmann 2013 Cohort 1297 69.6 67 (12.7) unclear SSTI 5 
Higgins 2009 Cohort 136 81.6 50.6 (11.3) unclear Unspecifie
d 
6 
Hu C.C 2012 Cohort 76362 61.5 62.2 (15.2) unclear H&N 7 
Jaar 2000 Cohort 4005 52.3 59.4 (15.4) 1, 2 Blood 6 
Lee CH 2012 Cohort 140 72.1 47.5 (15) unclear Bone 6 
Lee P.Y 2010 Cohort 260 76.1 58.3 (14.2) unclear SSTI 5 
Liao 2006 Cohort 337 17.5 − unclear SSTI 7 
Matros 2010 Cohort 21191 34.3 65 unclear SSTI 6 
Memmel 2004 Cohort 1256 60.8 39.4 (10.5) unclear Multiple 5 
Michalopoulos 2011 Case-Control 84 73.8 64.3 (11.5) unclear Blood 5 
Pablos-Mendez 1997 Case-Control 42656 58.2 − 1, 2 RTI 5 
Perez 2006 Case-Control 75723 50.4 − unclear RTI 5 
Pull ter Gunne 2009 Cohort 3174 40.1 55.6 (15.5) unclear SSTI 5 
Wang I.K 2012 Cohort 898 41 56 (14.6) unclear Blood 6 
Wilson 1995 Cohort 823 100 − unclear SSTI 4 
Yamashita 2000 Cohort 367 70 63.5 (10.4 1, 2 Unspecifie
d 
6 
Thomsen 2004 Case-Control 6578 47.3 − 1, 2 Blood 7 
Coskun 2000 Cohort 117 71 55 unclear SSTI 5 
Khurram 2004 Case-Control 57 57.9 46.5 (17.2) unclear Unspecifie
d 
5 
Wang Q 2013 Case-Control 13057 63.9 50.6 (17.5) 2 RTI 7 
Thanni 2004 Cohort 90 58.9 40 (17) unclear SSTI   5 
Bailey 1970 Cohort 1797 0 − unclear GU 5 
Baynes 1993 Case-Control 773 61.2 − unclear SSTI 7 
Picon 2007 Cohort 610 61.6 36 (14) unclear RTI   4 
Pezer 2013 Case-Control 109 − − unclear Viral   6 
Yoon 2013 Case-Control 344 0 54 (15.6) unclear GU 7 
Jackson 2013 Nested Case-
Control 
4730 − − unclear RTI 6 
Shah 2003 Cohort 1830820 51.7 60.9 (11.6) unclear Multiple 8 
Weitzman 2013 Cohort 2020709 − − unclear Viral 7 
Limmathurotsa 2010 Cohort − − − unclear Unspecifie 7 
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kul d 
Seminog 2013 Cohort − − − unclear Unspecifie
d 
7 
Abdul-Jabbar 2012 Cohort 6628 48.1 56.5 unclear SSTI 5 
Acott 2009 Cohort 38989 − 61.3 unclear Multiple 6 
Adrenito 2008 Cohort (Macthed 
cohort?) 
54 74.1 52.8 1, 2 SSTI 6 
Adetayo 2012 Cohort   297 − 51.7 (9.5) unclear Multiple 5 
Alserius 2008 Cohort 605 79 66 (9) 2 SSTI 7 
Altiparmak 2002 Case-Control 35 65.7 32.8 (10.3) unclear Unspecifie
d 
6 
Alvarsson 2012 Cohort 194 54.5 78.4 unclear Unspecifie
d 
6 
Al-Zaru 2010 Cohort 216 78.1 60.4 (9.1) unclear SSTI 6 
Appaduray 2013 Cohort 519 − 55 (17.7) 1, 2 Unspecifie
d 
6 
Aseeri 2008 Case-Control 188 43.6 − 1, 2 GI 6 
Atilgan 2014 Case-Control 305 65.9 25.7 (20.5) unclear Unspecifie
d 
5 
Backes 2014 Cohort 191 68.6 − unclear SSTI 6 
Baker 2012 Cohort 17715 49.6 − unclear RTI 6 
Behnke 2014 Cohort 396 53.3 57 (17) unclear SSTI 5 
Benin 2003 Case-Control 438 42 − 1, 2 Unspecifie
d 
6 
Bevilacqua 2011 Cohort 65 35.4 59.2 (14.6) unclear Blood 5 
Birgand 2013 Cohort 552 82.5 − unclear SSTI 6 
Bolognesi 2008 Cohort 751340 38.8 67.9 (11.5) unclear Multiple 6 
Bonds 2013 Cohort 254 53.9 56 (14) unclear SSTI 5 
Bowen 2005 Cohort 164 65.7 47 (18) unclear Unspecifie
d 
7 
Bozic 2014 Case-Control 587 55 − unclear Bone 6 
Bykowski 2011 Cohort 2755 37 52.9 (15) unclear SSTI 6 
Calderwood 2013 Cohort 524892 31.8 − unclear SSTI 6 
Carignan 2012 Case-Control 240 100 − unclear Multiple 7 
Chelemer 2002 Cohort 533 74.8 − unclear Unspecifie
d 
6 
Chen C-H 2006 Cohort 756 58.6 40.7 (12.2) unclear  6 
Chung S.D 2014 Cohort (Macthed 
cohort) 
30426 53.1 − unclear SSTI 7 
Chung C.P 2012 Cohort 169 0 63.8 (12.1) unclear GU 6 
Colombier 2013 Case-Control 222 73.4 64 (12) unclear SSTI 6 
Copeland 1994 Case-Control 73 0 67.6 unclear SSTI 5 
Crowson 2012 Cohort 584 27.7 57.5 (15.1) unclear Unspecifie
d 
7 
Daniels 2010 Cohort 243 21.4 55.1 unclear Infection 4 
Menezes 2008 Case-Control 240 56.7 44.63 unclear SSTI 5 
Demura 2009 Cohort 110 59.1 − unclear SSTI 4 
Donati 2014 Cohort 2782 67.8 − unclear Unspecifie
d 
6 
Dowesy 2008 Cohort 2206 44.2 − unclear Bone 7 
Dublin 2009 Case-Control 3360 50.8 − unclear RTI 7 
Dunkel 2012 Cohort 289 68.8 − unclear Unspecifie
d 
5 
Dziedzic 2009 Cohort 659 48.5 69.6 (12.4) unclear RTI 6 
Einsiedel 2013 Cohort 613 43.3 45.8 (15.7) uncelar Multiple 7 
Estrada 2003 Cohort 1574 66.8 63.5 (10.4) unclear Unspecifie
d 
6 
Fernandez-
Fresnedo 
2001 Cohort 107 71 51.4 (8.6) 1, 2 Unspecifie
d 
4 
Filsoufi 2007 Cohort 2725 76.4 65.4 (10.6) unclear Multiple 7 
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Flores-
Maldonado 
2001 Cohort 261 15.3 40 (12) unclear SSTI 6 
Friedman 2007 Cohort 4633 97 66.3 unclear SSTI 6 
Frisch 2010 Cohort 3112 46.2 56.5 (16) unclear Multiple 6 
Fusconi 2006 Cohort 115 − − unclear SSTI 5 
Gali 2012 Cohort 574 − 60.6 (13) unclear Unspecifie
d 
6 
Gansera 2006 Cohort 8666 78.6 65.1 (9.3) unclear SSTI 4 
Garber 1998 Cohort 360 100 59 unclear GU 6 
Garcia 2013 Cohort 92 73.9 54 (12.2) 2 Unspecifie
d 
5 
Haraway 2013 Cohort 135 21.5 57 unclear SSTI 6 
Harness 2010 Cohort 3003 31.2 − unclear SSTI 6 
Hayes 2014 Cohort 187 61.5 − 1, 2 Blood 6 
Hermsen 2011 Case-Control 352 59.1 60.3 unclear Unspecifie
d 
6 
Hirotani 1999 Cohort 420 75.7 64 unclear SSTI 7 
Hong 2014 Cohort 53249 48.4 − unclear GI 6 
Hughes 2013 Cohort 2110 65.5 71 (8.7) unclear Multiple 4 
Itagaki 2013 Cohort 1526360 73.3 64.8 (10.7) unclear SSTI 6 
Jeon 2012 Cohort 13800 47.4 − unclear SSTI 6 
Ji 2010 Cohort 393 70 74.2(3.1) unclear Multiple 6 
Ji 2009 Cohort 441 66.9 71.8 (3) unclear Multiple 6 
Jick 2006 Case-Control 2463 52.2 − unclear RTI 8 
Jih 2009 Cohort 1000000 49.6 − unclear Viral   7 
Joesoef 2012 Case-Control 675350 54.2 − unclear Viral   8 
Jovanovic 2006 Cohort 69 91.3 − unclear SSTI 4 
Kline 2009 Cohort 81 64.2 47.1 unclear SSTI 6 
Kluytmans 1995 Case-Control 160 75.6 62.7 (9.6) unclear SSTI 5 
Lee S-E 2010 Cohort 355 0 72.1 unclear SSTI 5 
Lee S-C 2004 Case-Control 101 55.4 63.7 (14.1) unclear Blood 5 
Lehtinen 2010 Nested Case-
Control 
469 39.9 51.6 (15.3) unclear SSTI 6 
Lemaire 2009 Cohort 1749 60.1 − unclear Blood 5 
Linney 2010 Case-Control 284 47.2 75.6 (12.5) unclear GI 5 
Malone 2002 Cohort 5031 95 61 (13) unclear SSTI 6 
Mangrulkar 2009 Cohort 489 58.7 − unclear Unspecifie
d 
5 
Masgala 2012 Case-Control 200 24 71.5 (16.8) unclear Unspecifie
d 
5 
Matsa 2001 Cohort 765 78.2 − unclear SSTI 5 
McCampbell 2002 Cohort 191 − − unclear Multiple 5 
Mekhail 2011 Cohort 707 42.3 46 (15) unclear SSTI 4 
Memon 2013 Cohort 60 38.3 43.8 (11.8) unclear SSTI 6 
Michalopoulos 2003 Case-Control 140 73.3 64.1 (9.9) unclear Blood 7 
Migita 2013 Cohort 604 40.7 59.6 (16.8) unclear Unspecifie
d 
7 
Miller 2007 Cohort 763 0 − 1, 2 SSTI 5 
Minakata 2012 Cohort 1421 77.4 68.3 (9.1) unclear Multiple 7 
Mittal 2014 Cohort 1651 62.7 76 (12) unclear Unspecifie
d 
6 
Mohamed 2009 Cohort 7733 76.5 64.9 (10.9) unclear Unspecifie
d 
7 
Mulaudzi 2009 Cohort 217 65 63.9 unclear SSTI 6 
Murphy 1992 Cohort 238 76.5 62.3 (10.8) unclear Unspecifie
d 
5 
Nasell 2011 Cohort 1782 46 − unclear SSTI 7 
Nelson 2014 Cohort 851 49.9 50 (13.7) unclear SSTI 5 
Olsen 2002 Cohort 1695 64.9 − unclear SSTI 6 
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Olsen 2008 Case-Control 273 − 52.4 unclear SSTI 6 
Osterhoff 2014 Cohort 261 73.2 46 (18.6) unclear SSTI 6 
Ovaska 2013 Case-Control 262 44 56 unclear SSTI 6 
Powe 1999 Cohort 4918 52.3 59.1 (15.8) unclear Blood 6 
Puskas 2012 Cohort 3527 70.9 62.6 (10.6) unclear SSTI   6 
Ramos 2008 Cohort 995 35 56.5 (15.9) unclear Unspecifie
d 
4 
Ridderstolpe 2001 Cohort 2992 72.4 65.4 (10.5) unclear SSTI   6 
Risnes 2010 Nested Case-
Control 
551 79.3 62.9 (9.5) unclear SSTI 5 
Rocco 2013 Cohort 1016 53.4 70.3 (13.1) unclear Unspecifie
d 
6 
Russo 2002 Cohort 2345 75.9 65.7 unclear SSTI   6 
Safdar 2005 Nested Case-
Control 
376 43.2 − unclear GU 5 
Sajja 2012 Cohort 3072 86.8 58.2 (8.6) unclear SSTI   7 
Sanderson 1990 Cohort 260 54.6 50.6 unclear Multiple 5 
sato 2010 Cohort 273 73.2 65.9 (11.9) unclear Multiple 6 
Schwartz 2004 Cohort 2063 99.6 − unclear SSTI   6 
Sepher 2009 Cohort 316 − 62 unclear Unspecifie
d 
6 
Shields 2013 Cohort 586 54.9 − unclear SSTI 7 
Simon 2005 Cohort 76 89.5 50.4 (2) unclear Unspecifie
d 
6 
Singh 2012 Cohort 903 15.8 48.1 (11.4) unclear SSTI   6 
Song 2012 Cohort 6848 26 66.9 (12.6) unclear SSTI 5 
Spinier 1998 Cohort 138 80.4 61.3 (12.2) unclear Unspecifie
d 
5 
Swenne 2005 Cohort 374 77.2 65.6 (8.4) unclear SSTI   7 
Tamayo 2012 Cohort 1610 39.1 67.8 (10.5) unclear RTI 7 
Tang 2004 Cohort 30102 72.6 − unclear SSTI   4 
Telzak 1991 Case-Control 155 51.6 67 unclear GI 5 
ter Gunne 2009 Cohort 3174 40.1 55.6 (15.5) unclear SSTI 6 
Togo 2007 Cohort 535 67.7 62.1 (10.5) unclear Multiple 5 
Torres 2006 Cohort 863 − 68.1(10.7) unclear SSTI 5 
Trieman 1994 Cohort 1023 67.3 66 unclear SSTI 5 
Trick 2000 Case-Control 127 − − unclear SSTI 5 
Troidle 2003 Cohort 162 53.7 55.4 (11.3) 1, 2 SSTI 6 
Vergidis 2012 Case-Control 50 − 58.5 unclear Bone 5 
Walcott 2014 Cohort 399 41.6 52.9 (0.8) unclear SSTI 7 
Wallaert 2012 Cohort 1977 67.2 − unclear SSTI 8 
Wang H. 2013 Cohort 707 32.7 72.5 (10.2) unclear Multiple 6 
Weichman 2013 Cohort 546 − 49.5 (11.1) unclear Unspecifie
d 
5 
Whang 2000 Cohort 900 84.3 − unclear Multiple 6 
Wilson 2003 Case-Control 258 − − unclear SSTI 6 
Wlazlo 2013 Cohort 226 64.6 59.2 (11.5) unclear SSTI 7 
Wong-McClure 2012 Case-Control 636 48.1 56.2 unclear GI 6 
Wu-H 2007 Case-Control 1180 63 60.5 (17.9) unclear RTI 5 
Wukich 2010 Cohort 1000 44.3 46.7 unclear SSTI   6 
Yamamoto 1992 Cohort 566 60.8 48 unclear SSTI   5 
Yamauchi 2013 Cohort 1438 58.8 67 (10) unclear Multiple 6 
Yavuz 2006 Cohort 991 71.9 57 (13.1) unclear SSTI 6 
Horne 2008 Case-Control 247 − − unclear SSTI 4 
Howard 2009 Cohort 136 44.1 54.6 (15.5) unclear SSTI 5 
Kuy 2013 Cohort 106 58.5 62 (14) unclear SSTI 5 
Orlander 1992 Case-Control 22778 0 60 unclear GU 6 
Raja 2013 Cohort 909 66.1 62.3 (13.5) unclear Multiple 6 
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Chen W. 2013 Cohort 177527 51 − unclear RTI 6 
Menderes 2010 Cohort 1000 0 29.8 (5.9) gestational SSTI 6 
Topal 2012 Cohort 162 51.2 65.6 (10.5) unclear RTI 4 
Guler 2006 Case-Control 204 43.1 47.7 (16.7) unclear GU 5 
Ricci 2014 Cohort 335 44.8 57 unclear SSTI 6 
Steele 2012 Cohort 22288 19.3 44.2 (9.8) 1, 2, 
gestational 
Multiple 6 
Chaichana 2014 Cohort 817 45.6 56 (14) unclear SSTI 7 
Hashimoto 2008 Cohort 242 54.5 − unclear Blood 6 
Park 2012 Cohort 770 74.8 37.9 unclear SSTI   6 
Troutman 2001 Nested Case-
Control 
56 69.6 − unclear SSTI 4 
Trussell 2008 Cohort 1482 71.9 67.1 (10.4) unclear SSTI 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
Appendix 2.C: Publication Bias Funnel Plots: 
 
(1) SSTI Infections/Cohort Studies: 
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(2) SSTI Infections/Case-Control Studies: 
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(3) RTI Infections/Cohort Studies: 
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(4) RTI Infections/Case-Control Studies: 
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(5) Genitourinary Infections/Cohort Studies: 
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(6) Blood Infections/Cohort Studies: 
 
 
 
 
 
 
 
 
 
 
 
 145 
 
(7) Viral Infections/Cohort Studies: 
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(8) Unspecified Infections/Cohort Studies: 
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Appendix 3.A: Exposure and Outcome Case Definitions: 
 
Exposure/Outcome 
 
Classification of Variables  
Diabetes CPCSSN Validated Case Definition using problem list (Diabetes, 
NIDDM, DM), Diagnostic codes (ICD-9: 250.0-250.9),  
medication list (insulin, oral antidiabetic agents, ATC code A10), 
and  
lab test results (HbA1c>7%, fasting BS>7) 
Infection Any infection-
Related Visit  
  Any record in EMR for any infection plus ICD-9 codes: 001-139, 
320-326, 391.1, 391.2, 421, 451, 685, 461.0-461.3, 461.8, 461.9, 
473.0-473.3, 473.8, 473.9, 460, 472.2, 462, 472.1, 463, 474.00, 
464.3, 464.5, 464.0, 476.0, 464.2, 476.1, 464.1, 491.8, 466, 490, 
491, 480-486, 510 + (041.0-041.9), 010-018, 590.0-590.3, 590.8, 
590.9, 595, 597, 601.0, 601.1, 601.9, 604, 607.1, 112.2, 611.0, 
614.0-614.5, 614.7, 615.9, 616.0, 616.1, 616.81, 090-099, V02.7, 
647.1, 110-118, 680, 681-682, 683, 684, 686, 728, 727.00, 727.02, 
727.05. 727.06, 729.4, 730.0-730.2, 730.3, 382.2, 711.0-711.9, 
003, 005, 004, 006, 009.0, 009.1, 531-535, 540-543, 567, 370.3, 
370.4, 372.0-372.3, 373.0, 373.1, 373.4-373.6, 373.8, 373.9, 076, 
380.0, 380.1, 381.0-381.5, 382.0-382.9, 384.0, 384.1, 383.0, 383.1, 
383.9, 052, 053, 054, 055, 056, 072, 487, 488, 070, J01, J02, J04, 
J05, D01, D06, G01, P01, P02, P03, A07A 
Infection Respiratory 
Tract 
Infections 
Upper 
respiratory 
tract 
infection 
Sinusitis  Any record in EMR plus ICD-9: 461.0-461.3, 461.8, 461.9, 473.0-
473.3, 473.8, 473.9 
Naso-
pharyngitis  
Any record in EMR plus ICD-9: 460, 472.2 
Pharyngitis  Any record in EMR plus ICD-9: 462, 472.1 
Tonsillitis  Any record in EMR plus ICD-9: 463, 474.00 
Epiglottitis  Any record in EMR plus ICD-9: 464.3, 464.5 
Laryngitis  Any record in EMR plus ICD-9: 464.0, 476.0 
Laryngo- Any record in EMR plus ICD-9: 464.2, 476.1 
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tracheitis  
Tracheitis  Any record in EMR plus ICD-9: 464.1, 491.8 
Lower 
respiratory 
tract 
infection 
Bronchitis Any record in EMR plus ICD-9: 466, 490, 491 
Pneumonia  Any record in EMR plus ICD-9: 480-486 
Empyema Any record in EMR plus ICD-9: 510 + (041.0-041.9) 
Tuberculosis  Any record in EMR plus ICD-9: 010-018 
    
Genitourinary 
Tract Infection 
Urinary 
tract 
infection 
Pyelonephritis  Any record in EMR plus ICD-9: 590.0-590.3, 590.8, 590.9 
Cystitis  Any record in EMR plus ICD-9: 595 
Urethritis  Any record in EMR plus ICD-9: 597 
Prostatitis  Any record in EMR plus ICD-9: 601.0, 601.1, 601.9 
Genital 
infection 
Epididymitis  Any record in EMR plus ICD-9: 604 
Balanitis  Any record in EMR plus ICD-9: 607.1, 112.2 
Pelvic 
Inflammatory 
Disease 
Any record in EMR plus ICD-9: 611.0, 614.0-614.5, 614.7, 615.9, 
616.0, 616.1, 616.81 
Syphilis  Any record in EMR plus ICD-9: 090-099 
Gonorrhea  Any record in EMR plus ICD-9: V02.7, 647.1 
    
Skin and Soft Tissue 
Infection 
Mycoses Any record in EMR plus ICD-9: 110-118 
Carbuncle and 
Furuncle 
Any record in EMR plus ICD-9: 680 
Cellulitis  Any record in EMR plus ICD-9: 681-682 
Lymphadenitis  Any record in EMR plus ICD-9: 683 
Impetigo  Any record in EMR plus ICD-9: 684 
Other  Any record in EMR plus ICD-9: 686 
    
Musculoskeletal Infection Myositis  Any record in EMR plus ICD-9: 728 
Synovitis Any record in EMR plus ICD-9: 727.00, 727.02, 727.05. 727.06 
Fasciitis  Any record in EMR plus ICD-9: 729.4 
Osteomyelitis  Any record in EMR plus ICD-9: 730.0-730.2 
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Periostitis  Any record in EMR plus ICD-9: 730.3 
Petrositis  Any record in EMR plus ICD-9: 382.2 
Arthropathy 
Associated 
Infection 
Any record in EMR plus ICD-9: 711.0-711.9 
    
Gastrointestinal Infection Salmonela 
(food 
poisoning) 
Any record in EMR plus ICD-9: 003, 005 
Shigellosis  Any record in EMR plus ICD-9: 004 
Amebiasis  Any record in EMR plus ICD-9: 006 
Gastroenteritis  Any record in EMR plus ICD-9: 009.0, 009.1 
Ulcer Any record in EMR plus ICD-9: 531-535 
Appendicitis  Any record in EMR plus ICD-9: 540-543 
Peritonitis  Any record in EMR plus ICD-9: 567 
    
Head & Neck Infections Conjunctivitis  Any record in EMR plus ICD-9: 370.3, 370.4, 372.0-372.3 
Blepharitis  Any record in EMR plus ICD-9: 373.0, 373.1, 373.4-373.6, 373.8, 
373.9 
Trachoma Any record in EMR plus ICD-9: 076 
Otitis Externa  Any record in EMR plus ICD-9: 380.0, 380.1 
Otitis Media  Any record in EMR plus ICD-9: 381.0-381.5, 382.0-382.9 
Myringitis  Any record in EMR plus ICD-9: 384.0, 384.1 
Mastoditis  Any record in EMR plus ICD-9: 383.0, 383.1, 383.9 
    
Viral Infections Chickenpox Any record in EMR plus ICD-9: 052 
Herpes Zoster  Any record in EMR plus ICD-9: 053 
Herpes Simplex Any record in EMR plus ICD-9: 054 
Measles Any record in EMR plus ICD-9: 055 
Rubella  Any record in EMR plus ICD-9: 056 
Mumps Any record in EMR plus ICD-9: 072 
Influenza  Any record in EMR plus ICD-9: 487, 488 
Hepatitis  Any record in EMR plus ICD-9: 070 
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 Medications Anti-infectives  Any record in EMR plus ATC code: J01, J02, J04, J05, D01, D06, 
G01, P01, P02, P03, A07A 
 
 
Appendix 3.B: Diagnostic Codes for Exclusion: 
 
Category  Classification of Variables  
Neoplasms Any record in EMR plus ICD-
9: 140-239 
AIDS/HIV Any record in EMR plus ICD-
9: 042-044 
Organ Transplant Kidney Any record in EMR plus ICD-
9: 55.6 
Liver Any record in EMR plus ICD-
9: 50.51 
Heart Any record in EMR plus ICD-
9: 37.52, 37.60, 37.65-37.67 
Medication use Immunosuppressant   Any record in EMR plus ATC 
code: L04 
Corticosteroids Any record in EMR plus ATC 
code: H02 
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Appendix 3.C: Timeline of Subject Recruitment and Follow-up: 
 
2007 2008 2009 2010 2011 2012 2013 2014 
Covariate 
measurement 
  
Cohort  
Entry  
Starts 
Cohort  
Entry  
Ends 
End of 
study: 
Minimum 
one year 
follow up 
 
Covariate Measurement Period: Starts January 1, 2007 to March 31, 2013. 
Cohort Entry Period: Starts January 1, 2008 to March 31, 2013. 
End of Study: Study will end March 31, 2014, which ensure at least one-year follow up. 
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Appendix 3.D: Case Definitions for Potential Confounders and Effect Modifiers: 
 
Category  Variable Name Classification of 
Variable 
Demographic  ID  De-identified ID 
Age Birth year 
Sex  Sex 
Lab Values HbA1c HbA1c 
Temperature >37.5 C Temperature 
WBC > 10,000 mcL WBC count 
Fasting Glucose Fasting Glucose 
BMI BMI 
Lipids Lipids 
Urine albumin creatinine ratio Urine albumin creatinine 
ratio 
Health Services 
Utilization 
Number of primary care 
physicians visits 
Number of visits 
Referrals to specialist  Number of referrals  
Number of lab tests ordered Number of lab tests 
Medications Anti-diabetic Medications Any record in EMR plus 
ATC code: A10A, A10B 
Immunosuppressant Any record in EMR plus 
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ATC code: L04 
Corticosteroids  Any record in EMR plus 
ATC code: H02 
Immunoglobulins Any record in EMR plus 
ATC code: J06 
Vaccines  Any record in EMR plus 
ATC code: J07 
Drugs for Acid-related Disorders Any record in EMR plus 
ATC code: A02A, 
A02B, A02X 
Respiratory System Agents Any record in EMR plus 
ATC code: R01-R07 
Lipid Modifying Agents Any record in EMR plus 
ATC code: C10 
Diabetes Comorbidities Microvascular Nephropathy 
 
Any record in EMR plus 
ICD-9: 250.40-250.43, 
583.81, 581.81 
Neuropathy Any record in EMR plus 
ICD-9: 250.60-250.63, 
337.1, 357.2, 536.3, 
353.5 
Retinopathy  Any record in EMR plus 
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 ICD-9: 250.50-250.53, 
362.00-362.07, 369.00-
369.90, 366.41, 265.41 
Macrovascular 
 
Peripheral 
vascular disease 
Any record in EMR plus 
ICD-9: 443.9, 441, 
785.4, V43.4, 38.48 
Cerebrovascular 
disease 
Any record in EMR plus 
ICD-9: 430-438 
Myocardial 
infarction 
Any record in EMR plus 
ICD-9: 410, 412 
Congestive 
heart failure 
Any record in EMR plus 
ICD-9: 428 
Non-Alcoholic Fatty Liver 
Disease 
Any record in EMR plus 
ICD-9: 571.8 
Obesity Any record in EMR plus 
ICD-9: 278, 783.1, 
V77.8 
Respiratory disease  Any record in EMR plus 
ICD-9: 460-519 
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Appendix 3.E: Odds Ratio (OR) of All Covariates for All Types of Infection: 
 
Any Infection:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 0.96 0.86-1.06 0.399 1.21 1.07-1.37 0.002 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.01 
1.20 
1.12 
 
0.94 
0.86 
 
0.89-1.14 
1.05-1.36 
0.99-1.27 
 
0.82-1.09 
0.73-1.00 
 
0.890 
0.006 
0.080 
 
0.443 
0.058 
 
0.97 
1.14 
1.10 
 
0.95 
0.77 
 
0.85-1.10 
1.00-1.31 
0.96-1.25 
 
0.82-1.11 
0.65-0.91 
 
0.636 
0.048 
0.174 
 
0.535 
0.002 
Sex (Female) 0.70 0.65-0.76 <0.001 0.73 0.68-0.80 <0.001 
Microvascular 1.70 0.85-3.39 0.130 1.53 0.75-3.12 0.244 
Macrovascular 0.77 0.56-1.05 0.104 0.75 0.54-1.05 0.091 
Respiratory 
Disease 
2.32 2.09-2.58 <0.001 1.45 1.28-1.64 <0.001 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.18 
 
 
1.94-2.18 
 
 
<0.001 
 
 
1.33 
 
 
1.02-1.73 
 
 
0.033 
Referral: 
0-1 
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≥2 1.45 1.17-1.80 0.001 1.06 0.84-1.32 0.621 
Lab Number: 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
 
1.21 
1.17 
1.05 
1.40 
1.76 
 
 
1.03-1.41 
0.93-1.47 
0.77-1.43 
0.88-2.18 
1.21-2.56 
 
 
0.017 
0.167 
0.757 
0.148 
0.003 
 
 
0.99 
0.96 
0.84 
1.02 
1.16 
 
 
0.84-1.17 
0.75-1.22 
0.61-1.16 
0.64-1.62 
0.79-1.71 
 
 
0.947 
0.734 
0.301 
0.935 
0.449 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.76 
3.12 
 
 
 
1.58-1.97 
2.82-2.46 
 
 
 
<0.001 
<0.001 
 
 
 
1.60 
2.54 
 
 
 
1.42-1.79 
1.26-2.85 
 
 
 
<0.001 
<0.001 
Vaccines 1.35 1.19-1.53 <0.001 1.09 0.95-1.25 0.193 
Drugs For Acid 
Related Disorders 
1.56 1.37-1.78 <0.001 1.24 1.08-1.44 0.003 
Respiratory Med 2.02 1.76-2.31 <0.001 1.22 1.04-1.43 0.012 
Lipid Medications 1.00 0.89-1.13 0.966 1.07 0.92-1.24 0.356 
Chf 1.42 0.64-3.14 0.384 1.20 0.52-2.74 0.671 
Fatty Liver 
Disease 
1.12 0.43-2.96 0.810 0.81 0.29-2.20 0.675 
Obesity 1.39 1.00-1.92 0.048 1.15 0.82-1.62 0.418 
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Head&Neck Infections:  
 
Variable Crude 
IRR 
95%CI P value Adjusted 
IRR 
95%CI P value 
Diabetes 0.90 0.74-1.11 0.328 1.10 0.87-1.39 0.428 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.94 
1.07 
1.08 
 
0.96 
0.92 
 
0.74-1.18 
0.85-1.35 
0.86-1.36 
 
0.73-1.27 
0.68-1.24 
 
0.579 
0.565 
0.494 
 
0.788 
0.576 
 
0.84 
1.00 
1.01 
 
0.96 
0.78 
 
0.66-1.08 
0.78-1.27 
0.79-1.28 
 
0.72-1.38 
0.56-1.08 
 
0.170 
0.990 
0.934 
 
0.785 
0.139 
Sex (Female) 0.80 0.69-0.92 0.002 0.83 0.71-0.97 0.017 
Microvascular 1.11 0.41-3.00 0.834 0.77 0.27-2.19 0.628 
Macrovascular 1.13 0.64-2.01 0.700 1.04 0.57-1.91 0.885 
Respiratory 
Disease 
2.11 1.80-2.48 <0.001 1.42 1.17-1.74 <0.001 
Doctor Visits: 
≤12 Visitis 
>12 Visits 
 
 
1.91 
 
 
1.34-2.74 
 
 
<0.001 
 
 
1.30 
 
 
0.89-1.89 
 
 
0.176 
Referral: 
0-1 
≥2 
 
 
1.64 
 
 
1.15-2.34 
 
 
0.006 
 
 
1.28 
 
 
0.89-1.86 
 
 
0.185 
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Lab Number: 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
 
1.39 
0.54 
0.67 
1.01 
1.25 
 
 
1.01-1.92 
0.29-1.00 
0.30-1.50 
0.34-2.97 
0.59-2.63 
 
 
0.046 
0.050 
0.332 
0.991 
0.562 
 
 
1.09 
0.37 
0.54 
0.91 
0.71 
 
 
0.78-1.53 
0.20-0.70 
0.24-1.22 
0.30-2.72 
0.33-1.55 
 
 
0.615 
0.002 
0.867 
0.867 
0.395 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.68 
2.72 
 
 
 
1.35-2.08 
2.28-3.26 
 
 
 
<0.001 
<0.001 
 
 
 
1.48 
2.14 
 
 
 
1.18-1.85 
1.74-2.63 
 
 
 
0.001 
<0.001 
Vaccines 1.73 1.41-2.13 <0.001 1.44 1.15-1.80 <0.001 
Drugs For Acid 
Related Disorders 
1.60 1.29-1.98 <0.001 1.51 1.25-1.81 <0.001 
Respiratory Med 1.78 1.44-2.19 <0.001 1.29 1.02-1.63 0.030 
Lipid Medications 1.01 0.80-1.27 0.925 1.00 0.76-1.32 0.983 
Heart Failure 1.37 0.38-4.98 0.631 1.50 0.39-5.71 0.552 
Fatty Liver 
Disease 
3.69 0.79-17.21 0.096 2.10 0.42-10.58 0.368 
Obesity 1.52 0.94-2.47 0.090 1.07 0.64-1.79 0.794 
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Respiratory Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 0.84 0.75-0.94 0.003 1.31 1.14-1.50 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.45 
1.73 
1.40 
 
0.93 
0.79 
 
1.27-1.66 
1.51-1.98 
1.22-1.61 
 
0.79-1.09 
0.65-0.95 
 
<0.001 
<0.001 
<0.001 
 
0.369 
0.011 
 
1.38 
1.65 
1.37 
 
0.97 
0.73 
 
1.19-1.59 
1.43-1.91 
1.18-1.59 
 
0.82-1.15 
0.60-0.89 
 
<0.001 
<0.001 
<0.001 
 
0.733 
0.002 
Sex (Female) 0.64 0.59-0.70 <0.001 0.68 0.62-0.75 <0.001 
Microvascular 0.95 0.49-1.84 0.883 0.84 0.41-1.69 0.620 
Macrovascular 0.63 0.44-0.91 0.014 0.84 0.57-1.23 0.370 
Respiratory 
Disease 
2.55 2.30-2.82 <0.001 1.86 1.65-2.11 <0.001 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
1.81 
 
 
1.45-2.26 
 
 
<0.001 
 
 
1.17 
 
 
0.92-1.48 
 
 
0.198 
Referral: 
0-1 
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≥2 1.87 1.51-2.31 <0.001 1.48 1.18-1.85 0.001 
Lab Number: 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
 
1.23 
1.08 
1.35 
1.54 
1.24 
 
 
1.03-1.47 
0.83-1.39 
0.95-1.92 
0.95-2.49 
0.83-1.85 
 
 
0.023 
0.561 
0.090 
0.076 
0.290 
 
 
1.16 
0.95 
1.29 
1.28 
0.92 
 
 
0.96-1.39 
0.73-1.25 
0.89-1.86 
0.77-2.10 
0.61-1.41 
 
 
0.131 
0.743 
0.177 
0.337 
0.719 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.55 
2.73 
 
 
 
1.37-1.74 
2.46-3.03 
 
 
 
<0.001 
<0.001 
 
 
 
1.30 
1.96 
 
 
 
1.14-1.46 
1.74-2.22 
 
 
 
<0.001 
<0.001 
Vaccines 1.01 0.89-1.16 0.854 0.88 0.76-1.01 0.080 
Drugs For Acid 
Related Disorders 
1.34 1.17-1.54 <0.001 1.18 1.02-1.37 0.027 
Respiratory Med 1.87 1.64-2.13 <0.001 1.06 0.91-1.23 0.467 
Lipid Medications 0.71 0.62-0.82 <0.001 0.88 0.74-1.04 0.139 
Heart Failure 0.92 0.40-2.14 0.852 1.13 0.47-2.74 0.779 
Fatty Liver 
Disease 
0.73 0.24-2.21 0.581 0.56 0.18-1.75 0.318 
Obesity 1.37 0.99-1.89 0.056 1.13 0.81-1.60 0.468 
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Gastrointestinal Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.38 1.15-1.67 <0.001 1.41 1.13-1.75 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.75 
0.73 
0.95 
 
0.94 
1.04 
 
0.58-0.95 
0.57-0.94 
0.75-1.22 
 
0.71-1.23 
0.78-1.38 
 
0.019 
0.014 
0.703 
 
0.638 
0.801 
 
0.79 
0.76 
0.92 
 
0.89 
0.94 
 
0.64-0.95 
0.61-0.92 
0.90-1.31 
 
0.87-1.33 
0.89-1.39 
 
0.080 
0.043 
0.504 
 
0.443 
0.706 
Sex (Female) 1.15 0.99-1.34 0.074 1.16 0.99-1.35 0.070 
Microvascular 2.93 1.10-7.78 0.031 2.21 0.77-6.31 0.138 
Macrovascular 1.05 0.59-1.86 0.872 0.79 0.43-1.46 0.461 
Respiratory 
Disease 
1.22 1.02-1.46 0.032 0.98 0.79-1.23 0.891 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.46 
 
 
1.78-3.41 
 
 
<0.001 
 
 
2.05 
 
 
1.46-2.90 
 
 
<0.001 
Referral: 
0-1 
≥2 
 
 
1.11 
 
 
0.72-1.72 
 
 
0.619 
 
 
0.87 
 
 
0.55-1.37 
 
 
0.549 
Lab Number:       
 162 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
0.69 
0.75 
0.92 
1.17 
1.60 
 
0.47-1.01 
0.42-1.34 
0.44-1.94 
0.48-2.87 
0.80-3.19 
 
0.060 
0.334 
0.837 
0.731 
0.182 
 
0.60 
0.62 
0.79 
0.91 
1.19 
 
0.40-0.89 
0.34-1.14 
0.37-1.69 
0.36-2.31 
0.58-2.45 
 
0.012 
0.125 
0.548 
0.850 
0.631 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.44 
1.67 
 
 
 
1.16-1.79 
1.38-2.02 
 
 
 
0.001 
<0.001 
 
 
 
1.47 
1.71 
 
 
 
1.17-1.84 
1.36-2.13 
 
 
 
0.120 
<0.001 
Vaccines 1.23 0.97-1.54 0.082 1.04 0.81-1.34 0.745 
Drugs For Acid 
Related Disorders 
2.22 1.79-2.76 <0.001 1.89 1.49-2.38 <0.001 
Respiratory Med 1.02 0.80-1.31 0.840 0.78 0.58-1.03 0.083 
Lipid Medications 1.31 1.04-1.64 0.021 0.93 0.71-1.22 0.618 
Heart Failure 0.71 0.15-3.29 0.666 0.45 0.09-2.15 0.319 
Fatty Liver 
Disease 
0.39 0.05-3.17 0.379 0.24 0.03-2.05 0.191 
Obesity 1.34 0.75-2.38 0.471 1.22 0.67-2.24 0.510 
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Genitourinary Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.10 0.94-1.29 0.238 1.42 1.17-1.73 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.06 
0.97 
1.04 
 
1.04 
1.19 
 
0.77-1.29 
0.79-1.19 
0.85-1.28 
 
0.83-1.31 
0.94-1.52 
 
0.552 
0.791 
0.691 
 
0.727 
0.150 
 
0.94 
0.82 
0.98 
 
1.00 
0.93 
 
0.76-1.16 
0.66-1.02 
0.79-1.22 
 
0.78-1.27 
0.71-1.21 
 
0.580 
0.080 
0.889 
 
0.975 
0.585 
Sex (Female) 0.31 0.27-0.36 <0.001 0.32 0.27-0.37 <0.001 
Microvascular 0.89 0.36-2.23 0.809 0.59 0.22-1.54 0.281 
Macrovascular 1.15 0.72-1.84 0.549 1.21 0.73-2.02 0.460 
Respiratory 
Disease 
1.77 1.54-2.03 <0.001 1.09 0.92-1.30 0.315 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.52 
 
 
1.93-3.28 
 
 
<0.001 
 
 
1.63 
 
 
1.22-2.18 
 
 
0.001 
Referral: 
0-1 
≥2 
 
 
1.16 
 
 
0.84-1.59 
 
 
0.920 
 
 
0.84 
 
 
0.60-1.17 
 
 
0.308 
Lab Number:       
 164 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.37 
0.98 
1.05 
0.67 
1.48 
 
1.05-1.81 
0.65-1.49 
0.60-1.85 
0.23-1.91 
0.82-2.67 
 
0.022 
0.944 
0.866 
0.450 
0.192 
 
1.09 
0.72 
0.71 
0.37 
0.86 
 
0.81-1.46 
0.46-1.12 
0.39-1.27 
0.12-1.12 
0.46-1.61 
 
0.572 
0.146 
0.248 
0.079 
0.648 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.65 
2.81 
 
 
 
1.38-1.98 
2.41-3.27 
 
 
 
<0.001 
<0.001 
 
 
 
1.55 
2.43 
 
 
 
1.28-1.88 
2.04-2.90 
 
 
 
<0.001 
<0.001 
Vaccines 1.36 1.14-1.63 <0.001 0.99 0.81-1.21 0.948 
Drugs For Acid 
Related Disorders 
1.79 1.49-2.14 <0.001 1.36 1.11-1.67 0.003 
Respiratory Med 1.81 1.52-2.17 <0.001 1.25 1.01-1.54 0.038 
Lipid Medications 1.03 0.85-1.25 0.770 0.98 0.77-1.25 0.882 
Heart Failure 1.91 0.76-4.78 0.167 1.41 0.53-3.72 0.490 
Fatty Liver 
Disease 
4.42 1.30-15.07 0.017 4.66 1.20-18.17 0.027 
Obesity 1.61 1.04-2.51 0.033 1.32 0.81-2.14 0.261 
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Skin&Soft Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.43 1.21-1.69 <0.001 1.65 1.36-2.01 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.89 
1.04 
1.05 
 
0.88 
1.17 
 
0.71-1.10 
0.84-1.30 
0.84-1.32 
 
0.68-1.14 
0.90-1.51 
 
0.286 
0.696 
0.636 
 
0.334 
0.240 
 
0.95 
1.07 
1.08 
 
0.86 
1.04 
 
0.76-1.20 
0.86-1.35 
0.86-1.35 
 
0.66-1.11 
0.79-1.37 
 
0.678 
0.533 
0.527 
 
0.249 
0.778 
Sex (Female) 1.05 0.91-1.20 0.497 1.07 0.93-1.23 0.323 
Microvascular 2.84 1.27-6.34 0.011 1.86 0.80-4.28 0.146 
Macrovascular 1.24 0.77-1.99 0.378 1.04 0.63-1.72 0.880 
Respiratory 
Disease 
1.65 1.41-1.93 <0.001 1.33 1.10-1.61 0.004 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.42 
 
 
1.79-3.26 
 
 
<0.001 
 
 
1.89 
 
 
1.37-2.60 
 
 
<0.001 
Referral: 
0-1 
≥2 
 
 
1.02 
 
 
0.70-1.49 
 
 
0.901 
 
 
0.80 
 
 
0.54-1.18 
 
 
0.263 
Lab Number:       
 166 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.48 
0.62 
1.96 
0.51 
1.25 
 
1.11-1.99 
0.36-1.06 
1.13-3.41 
0.15-1.70 
0.61-2.56 
 
0.009 
0.081 
0.017 
0.276 
0.549 
 
1.32 
0.51 
1.65 
0.43 
0.98 
 
0.98-1.79 
0.29-0.88 
0.93-2.93 
0.13-1.45 
0.46-2.09 
 
0.070 
0.015 
0.088 
0.174 
0.965 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.29 
1.73 
 
 
 
1.06-1.56 
1.47-2.05 
 
 
 
0.011 
<0.001 
 
 
 
1.25 
1.53 
 
 
 
1.02-1.53 
1.26-1.87 
 
 
 
0.033 
<0.001 
Vaccines 1.20 0.98-1.48 0.075 1.01 0.82-1.26 0.907 
Drugs For Acid 
Related Disorders 
1.44 1.17-1.78 0.001 1.19 0.95-1.49 0.125 
Respiratory Med 1.47 1.19-1.82 <0.001 1.03 0.81-1.31 0.809 
Lipid Medications 1.10 0.88-1.36 0.019 0.87 0.67-1.12 0.276 
Heart Failure 1.12 0.31-3.96 0.863 0.71 0.19-2.66 0.613 
Fatty Liver 
Disease 
0.84 0.18-3.90 0.824 0.60 0.12-2.91 0.524 
Obesity 1.90 1.18-3.06 0.002 1.44 0.87-2.36 0.152 
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Musculoskeletal Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 0.97 0.82-1.14 0.714 1.05 0.87-1.28 0.606 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.59 
0.80 
1.40 
 
0.87 
0.43 
 
0.48-0.72 
0.65-0.97 
1.16-1.68 
 
0.70-1.09 
0.32-0.58 
 
<0.001 
0.024 
<0.001 
 
0.227 
<0.001 
 
0.57 
0.76 
1.40 
 
0.88 
0.38 
 
0.47-0.70 
0.62-0.93 
1.15-1.69 
 
0.70-1.11 
0.27-0.51 
 
<0.001 
0.008 
0.001 
 
0.273 
<0.001 
Sex (Female) 0.65 0.57-0.73 <0.001 0.62 0.54-0.71 <0.001 
Microvascular 2.21 1.04-4.69 0.039 2.12 0.97-4.67 0.061 
Macrovascular 0.71 0.40-1.26 0.240 0.83 0.45-1.51 0.539 
Respiratory 
Disease 
1.23 1.07-1.43 0.005 0.97 0.81-1.16 0.734 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
1.51 
 
 
1.11-2.04 
 
 
0.008 
 
 
1.15 
 
 
0.83-1.59 
 
 
0.400 
Referral: 
0-1 
≥2 
 
 
2.02 
 
 
1.52-2.68 
 
 
<0.001 
 
 
1.75 
 
 
1.30-2.35 
 
 
<0.001 
Lab Number:       
 168 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.03 
1.58 
0.96 
0.99 
1.11 
 
0.78-1.36 
1.10-2.27 
0.57-1.63 
0.45-2.17 
0.61-2.03 
 
0.815 
0.013 
0.895 
0.983 
0.724 
 
0.92 
1.41 
0.85 
0.72 
0.82 
 
0.69-1.23 
0.97-2.05 
0.50-1.46 
0.32-1.60 
0.44-1.53 
 
0.579 
0.074 
0.565 
0.417 
0.536 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.21 
1.57 
 
 
 
1.01-1.44 
1.35-1.82 
 
 
 
0.033 
<0.001 
 
 
 
1.16 
1.46 
 
 
 
0.96-1.40 
1.23-1.74 
 
 
 
0.113 
<0.001 
Vaccines 1.06 0.88-1.29 0.514 1.03 0.84-1.27 0.757 
Drugs For Acid 
Related Disorders 
1.56 1.29-1.87 <0.001 1.38 1.13-1.69 0.002 
Respiratory Med 1.24 1.02-1.50 0.028 0.96 0.77-1.20 0.755 
Lipid Medications 0.97 0.79-1.18 0.758 0.97 0.77-1.23 0.802 
Heart Failure 1.60 0.59-4.31 0.354 2.52 0.89-7.13 0.081 
Fatty Liver 
Disease 
2.12 0.63-7.10 0.223 1.70 0.49-5.93 0.403 
Obesity 1.25 0.80-1.95 0.320 1.01 0.63-1.62 0.963 
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Viral Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.21 0.95-1.55 0.115 1.11 0.83-1.47 0.485 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.73 
0.73 
0.99 
 
1.13 
1.06 
 
0.53-1.00 
0.53-1.01 
0.73-1.35 
 
0.80-1.58 
0.73-1.54 
 
0.048 
0.059 
0.958 
 
0.490 
0.742 
 
0.72 
0.69 
1.02 
 
1.03 
0.84 
 
0.52-1.00 
0.49-0.97 
0.74-1.40 
 
0.73-1.46 
0.57-1.26 
 
0.055 
0.035 
0.907 
 
0.860 
0.404 
Sex (Female) 0.86 0.71-1.05 0.140 0.84 0.68-1.03 0.090 
Microvascular 3.32 0.96-11.44 0.058 2.15 0.58-8.00 0.254 
Macrovascular 1.14 0.53-2.47 0.740 0.82 0.36-1.85 0.635 
Respiratory 
Disease 
1.70 1.36-2.11 <0.001 1.31 1.00-1.72 0.051 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
1.48 
 
 
0.95-2.32 
 
 
0.085 
 
 
1.10 
 
 
0.68-1.78 
 
 
0.698 
Referral: 
0-1 
≥2 
 
 
0.82 
 
 
0.46-1.46 
 
 
0.507 
 
 
0.63 
 
 
0.35-1.15 
 
 
0.133 
Lab Number:       
 170 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.43 
0.99 
1.07 
2.13 
0.60 
 
0.96-2.11 
0.55-1.79 
0.46-2.48 
0.83-5.45 
0.18-2.00 
 
0.074 
0.976 
0.869 
0.114 
0.407 
 
1.16 
0.76 
0.81 
1.90 
0.43 
 
0.77-1.75 
0.41-1.41 
0.34-1.94 
0.72-4.99 
0.13-1.46 
 
0.462 
0.382 
0.645 
0.191 
0.176 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.18 
1.68 
 
 
 
0.89-1.57 
1.33-2.13 
 
 
 
0.240 
<0.001 
 
 
 
1.11 
1.40 
 
 
 
0.82-1.49 
1.06-1.86 
 
 
 
0.503 
0.017 
Vaccines 2.27 1.76-2.92 <0.001 1.99 1.52-2.61 <0.001 
Drugs For Acid 
Related Disorders 
1.48 1.11-1.96 0.007 1.13 0.83-1.54 0.425 
Respiratory Med 1.65 1.25-2.19 <0.001 1.17 0.84-1.63 0.354 
Lipid Medications 1.32 0.98-1.76 0.063 1.08 0.77-1.52 0.660 
Heart Failure 0.58 0.07-4.74 0.612 0.42 0.05-3.54 0.428 
Fatty Liver 
Disease 
10.24 2.43-43.19 0.002 12.28 2.79-54.14 <0.001 
Obesity 1.93 1.05-3.54 0.033 1.67 0.89-3.13 0.107 
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Appendix 3.F: Odds Ratio (OR) Of All Covariates For All Types Of Infection 1-Year 
Period: 
 
Any Infection:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.06 0.95-1.18 0.290 1.37 1.21-1.55 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.27 
1.18 
1.26 
 
1.05 
1.17 
 
1.12-1.45 
1.04-1.35 
1.10-1.44 
 
0.91-1.23 
0.99-1.38 
 
<0.000 
0.012 
0.001 
 
0.482 
0.063 
 
1.24 
1.13 
1.24 
 
1.07 
1.05 
 
1.09-1.43 
0.98-1.30 
1.07-1.42 
 
0.92-1.26 
0.88-1.25 
 
0.002 
0.086 
0.003 
 
0.369 
0.610 
Sex (Female) 0.69 0.63-0.75 <0.001 0.72 0.66-0.78 <0.001 
Microvascular 2.60 1.36-4.97 0.004 2.12 1.06-4.25 0.033 
Macrovascular 1.00 0.72-1.40 0.989 0.93 0.65-1.33 0.695 
Respiratory 
Disease 
2.19 1.99-2.41 <0.001 1.48 1.31-1.66 <0.001 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.48 
 
 
2.00-3.07 
 
 
<0.001 
 
 
1.61 
 
 
1.28-2.03 
 
 
<0.001 
Referral:       
 172 
0-1 
≥2 
 
1.47 
 
1.20-1.80 
 
<0.001 
 
1.09 
 
0.88-1.35 
 
0.435 
Lab Number: 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
 
1.04 
1.11 
0.98 
1.20 
1.54 
 
 
0.89-1.23 
0.87-1.41 
0.70-1.37 
0.75-1.92 
1.07-2.22 
 
 
0.602 
0.400 
0.909 
0.443 
0.019 
 
 
0.87 
0.89 
0.78 
0.86 
1.01 
 
 
0.73-1.03 
0.69-1.15 
0.55-1.11 
0.53-1.40 
0.69-1.48 
 
 
0.104 
0.386 
0.165 
0.550 
0.945 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.64 
2.65 
 
 
 
1.46-1.84 
2.40-2.93 
 
 
 
<0.001 
<0.001 
 
 
 
1.48 
2.14 
 
 
 
1.25-1.47 
1.91-2.40 
 
 
 
<0.001 
<0.001 
Vaccines 1.32 1.17-1.50 0.026 1.04 0.91-1.19 0.561 
Drugs For Acid 
Related Disorders 
1.61 1.41-1.83 <0.001 1.28 1.12-1.48 <0.001 
Respiratory Med 1.88 1.66-2.14 <0.001 1.16 1.00-1.34 0.047 
Lipid Medications 0.98 0.86-1.11 0.333 0.96 0.82-1.12 0.605 
Heart Failure 1.54 1.03-2.30 0.034 1.63 0.75-3.56 0.217 
Fatty Liver 
Disease 
1.48 0.60-3.67 0.391 1.19 0.48-2.97 0.708 
Obesity 1.29 0.94-1.78 0.115 1.04 0.74-1.45 0.823 
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Head&Neck Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 0.83 0.59-1.17 0.285 1.12 0.75-1.67 0.573 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.40 
1.26 
1.64 
 
0.97 
1.24 
 
0.96-2.04 
0.85-1.87 
1.13-2.40 
 
0.60-1.58 
0.76-2.04 
 
0.082 
0.253 
0.010 
 
0.911 
0.392 
 
1.23 
1.13 
1.53 
 
1.05 
1.21 
 
0.82-1.85 
0.74-1.73 
1.03-2.27 
 
0.63-1.74 
0.71-2.06 
 
0.312 
0.564 
0.033 
 
0.849 
0.484 
Sex (Female) 0.76 0.60-0.97 0.030 0.85 0.65-1.09 0.201 
Microvascular 1.46 0.30-6.98 0.638 0.96 0.19-4.88 0.959 
Macrovascular 1.08 0.37-3.15 0.895 0.93 0.29-2.97 0.903 
Respiratory 
Disease 
2.06 1.59-2.68 <0.001 1.24 0.90-1.71 0.192 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
1.86 
 
 
1.04-3.32 
 
 
0.036 
 
 
1.10 
 
 
0.59-2.06 
 
 
0.762 
Referral: 
0-1 
≥2 
 
 
2.49 
 
 
1.53-4.03 
 
 
<0.001 
 
 
1.85 
 
 
1.10-3.13 
 
 
0.021 
Lab Number:       
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0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.70 
0.91 
0.31 
0.67 
1.12 
 
1.09-2.66 
0.40-2.06 
0.04-2.39 
0.08-5.27 
0.38-3.37 
 
0.009 
0.593 
0.238 
0.533 
0.546 
 
1.44 
0.69 
0.37 
0.69 
0.87 
 
0.90-2.32 
0.29-1.64 
0.04-2.61 
0.08-5.73 
0.28-2.70 
 
0.130 
0.404 
0.297 
0.732 
0.813 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.58 
3.36 
 
 
 
1.11-2.24 
2.53-4.45 
 
 
 
0.010 
<0.001 
 
 
 
1.42 
2.76 
 
 
 
0.98-2.04 
1.99-3.82 
 
 
 
0.060 
<0.001 
Vaccines 1.45 1.03-2.03 0.033 1.14 0.78-1.66 0.489 
Drugs For Acid 
Related Disorders 
1.38 0.96-1.96 0.079 1.02 0.69-1.52 0.905 
Respiratory Med 1.70 1.22-2.39 0.002 1.07 0.73-1.59 0.717 
Lipid Medications 0.80 0.53-1.21 0.298 0.87 0.54-1.40 0.557 
Heart Failure 1.21 0.14-10.45 0.863 1.17 0.12-11.07 0.893 
Fatty Liver 
Disease 
4.18 0.26-67.62 0.313 4.10 0.16-
106.71 
0.396 
Obesity 1.11 0.42-2.91 0.835 0.86 0.30-2.46 0.778 
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Respiratory Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 0.94 0.81-1.10 0.470 1.45 1.21-1.74 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.41 
1.45 
1.35 
 
0.86 
0.96 
 
1.17-1.70 
1.20-1.75 
1.11-1.63 
 
0.68-1.09 
0.75-1.23 
 
<0.001 
<0.001 
0.002 
 
0.218 
0.735 
 
1.38 
1.37 
1.30 
 
0.92 
0.93 
 
1.14-1.69 
1.12-1.67 
1.06-1.59 
 
0.72-1.17 
0.71-1.21 
 
0.001 
0.002 
0.010 
 
0.501 
0.595 
Sex (Female) 0.69 0.62-0.78 <0.001 0.77 0.68-0.87 <0.001 
Microvascular 1.48 0.66-3.33 0.342 1.13 0.47-2.70 0.697 
Macrovascular 0.59 0.34-1.01 0.056 0.67 0.38-1.19 0.267 
Respiratory 
Disease 
2.86 2.52-3.24 <0.001 1.97 1.69-2.30 <0.001 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.51 
 
 
1.95-3.24 
 
 
<0.001 
 
 
1.56 
 
 
1.18-2.06 
 
 
0.002 
Referral: 
0-1 
≥2 
 
 
1.35 
 
 
1.03-1.77 
 
 
0.030 
 
 
0.95 
 
 
0.71-1.27 
 
 
0.735 
Lab Number:       
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0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.31 
1.17 
1.03 
1.12 
1.67 
 
1.04-1.63 
0.83-1.63 
0.64-1.67 
0.57-2.19 
1.01-2.74 
 
0.019 
0.364 
0.902 
0.741 
0.044 
 
1.15 
0.95 
0.89 
0.79 
1.20 
 
0.91-1.46 
0.66-1.35 
0.54-1.47 
0.39-1.60 
0.70-2.04 
 
0.248 
0.767 
0.652 
0.523 
0.503 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.63 
2.87 
 
 
 
1.39-1.93 
2.51-3.29 
 
 
 
<0.001 
<0.001 
 
 
 
1.30 
1.90 
 
 
 
1.10-1.55 
1.62-2.22 
 
 
 
0.003 
<0.001 
Vaccines 1.19 1.00-1.41 0.053 0.93 0.77-1.13 0.475 
Drugs For Acid 
Related Disorders 
1.76 1.49-2.08 <0.001 1.48 1.23-1.78 <0.001 
Respiratory Med 2.13 1.81-2.51 <0.001 1.12 0.93-1.35 0.243 
Lipid Medications 0.70 0.58-0.86 0.001 0.71 0.55-0.90 0.005 
Heart Failure 0.97 0.35-2.69 0.948 0.82 0.27-2.48 0.720 
Fatty Liver 
Disease 
0.82 0.17-3.90 0.804 0.55 0.11-2.81 0.473 
Obesity 1.61 1.07-2.44 0.023 1.25 0.80-1.96 0.318 
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Gastrointestinal Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.78 1.36-2.34 <0.001 1.71 1.22-2.39 0.002 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.85 
0.72 
1.03 
 
1.22 
1.64 
 
0.57-1.27 
0.47-1.10 
0.69-1.53 
 
0.80-1.87 
1.08-2.49 
 
0.440 
0.127 
0.876 
 
0.359 
0.020 
 
0.94 
0.77 
0.97 
 
1.15 
1.38 
 
0.61-1.44 
0.50-1.20 
0.64-1.46 
 
0.73-1.80 
0.88-2.18 
 
0.774 
0.255 
0.884 
 
0.549 
0.161 
Sex (Female) 1.17 0.91-1.49 0.211 1.16 0.89-1.50 0.263 
Microvascular 5.25 1.60-17.24 0.006 3.41 0.95-12.21 0.059 
Macrovascular 1.61 0.68-3.80 0.279 1.01 0.40-2.55 0.977 
Respiratory 
Disease 
1.17 0.88-1.55 0.284 0.84 0.59-1.20 0.344 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.50 
 
 
1.51-4.15 
 
 
<0.001 
 
 
1.80 
 
 
1.03-3.13 
 
 
0.038 
Referral: 
0-1 
≥2 
 
 
1.19 
 
 
0.65-2.19 
 
 
0.574 
 
 
0.95 
 
 
0.49-1.83 
 
 
0.877 
Lab Number:       
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0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
0.56 
0.57 
0.83 
0.71 
1.45 
 
0.31-0.99 
0.22-1.47 
0.28-2.48 
0.16-3.17 
0.52-4.01 
 
0.048 
0.249 
0.746 
0.650 
0.474 
 
0.46 
0.38 
0.61 
0.61 
1.06 
 
0.26-0.84 
0.14-1.05 
0.20-1.89 
0.13-2.88 
0.35-3.18 
 
0.011 
0.062 
0.396 
0.530 
0.912 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.28 
1.95 
 
 
 
0.90-1.82 
1.45-2.61 
 
 
 
0.164 
<0.001 
 
 
 
1.41 
2.27 
 
 
 
0.98-2.05 
1.59-3.22 
 
 
 
0.067 
<0.001 
Vaccines 1.27 0.88-1.82 0.195 0.93 0.62-1.38 0.722 
Drugs For Acid 
Related Disorders 
2.66 1.92-3.67 <0.001 1.93 1.35-2.75 <0.001 
Respiratory Med 1.16 0.80-1.68 0.425 0.93 0.60-1.44 0.737 
Lipid Medications 1.71 1.22-2.39 0.002 1.03 0.68-1.55 0.897 
Heart Failure 1.04 0.12-9.20 0.970 0.52 0.06-4.83 0.569 
Fatty Liver 
Disease 
- - - - - - 
Obesity 0.92 0.32-2.65 0.872 1.00 0.33-3.05 0.993 
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Genitourinary Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.34 1.06-1.69 0.248 1.86 1.39-2.50 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.04 
0.82 
1.16 
 
1.05 
1.62 
 
0.77-1.42 
0.58-1.15 
0.84-1.61 
 
0.73-1.51 
1.14-2.31 
 
0.786 
0.244 
0.353 
 
0.774 
0.007 
 
0.98 
0.73 
1.14 
 
0.97 
1.28 
 
0.70-1.38 
0.51-1.05 
0.81-1.61 
 
0.66-1.43 
0.87-1.90 
 
0.929 
0.093 
0.449 
 
0.877 
0.206 
Sex (Female) 0.34 0.27-0.43 <0.001 0.35 0.28-0.45 <0.001 
Microvascular 1.78 0.56-5.61 0.324 1.11 0.32-3.85 0.871 
Macrovascular 2.00 1.04-3.85 0.037 2.20 1.06-4.56 <0.034 
Respiratory 
Disease 
1.87 1.52-2.30 <0.001 1.14 0.88-1.47 0.330 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
2.65 
 
 
1.83-3.85 
 
 
<0.001 
 
 
1.55 
 
 
1.03-2.35 
 
 
0.037 
Referral: 
0-1 
≥2 
 
 
1.01 
 
 
0.63-1.61 
 
 
0.955 
 
 
0.77 
 
 
0.47-1.27 
 
 
0.317 
Lab Number:       
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0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.32 
1.11 
1.22 
0.94 
1.69 
 
0.91-1.92 
0.61-2.01 
0.59-2.51 
0.27-3.25 
0.72-3.97 
 
0.137 
0.739 
0.585 
0.929 
0.230 
 
1.03 
0.80 
0.67 
0.41 
0.92 
 
0.69-1.55 
0.42-1.51 
0.32-1.43 
0.11-1.57 
0.36-2.30 
 
0.865 
0.489 
0.303 
0.194 
0.854 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
2.17 
3.30 
 
 
 
1.64-2.85 
2.61-4.16 
 
 
 
<0.001 
<0.001 
 
 
 
2.13 
3.02 
 
 
 
1.58-2.86 
2.30-3.96 
 
 
 
<0.001 
<0.001 
Vaccines 1.59 1.22-2.07 <0.001 1.11 0.83-1.48 0.483 
Drugs For Acid 
Related Disorders 
2.10 1.61-2.72 <0.001 1.50 1.11-2.02 0.008 
Respiratory Med 1.72 1.31-2.26 <0.001 1.09 0.80-1.51 0.574 
Lipid Medications 1.07 0.79-1.44 0.658 0.77 0.53-1.13 0.187 
Heart Failure 2.95 0.88-9.86 0.080 1.91 0.53-6.91 0.323 
Fatty Liver 
Disease 
5.14 1.01-26.09 0.048 4.32 0.77-24.03 0.095 
Obesity 1.28 0.63-2.57 0.495 1.04 0.49-2.21 0.908 
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Skin&Soft Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.81 1.40-2.34 <0.001 1.96 1.43-2.69 <0.001 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
1.08 
1.15 
1.16 
 
1.43 
1.27 
 
0.74-1.58 
0.78-1.69 
0.78-1.71 
 
0.94-2.17 
0.80-2.01 
 
0.682 
0.476 
0.465 
 
0.097 
0.312 
 
1.24 
1.23 
1.21 
 
1.31 
1.07 
 
0.83-1.86 
0.82-1.85 
0.81-1.82 
 
0.84-2.03 
0.65-1.75 
 
0.290 
0.321 
0.352 
 
0.227 
0.787 
Sex (Female) 1.05 0.83-1.33 0.676 1.06 0.83-1.35 0.656 
Microvascular 5.92 1.88-18.63 0.002 3.74 1.05-13.26 0.041 
Macrovascular 1.63 0.68-3.92 0.270 1.05 0.40-2.70 0.925 
Respiratory 
Disease 
1.81 1.40-2.36 <0.001 1.50 1.08-2.10 0.016 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
3.14 
 
 
1.93-5.11 
 
 
<0.001 
 
 
2.36 
 
 
1.40-4.00 
 
 
0.001 
Referral: 
0-1 
≥2 
 
 
1.50 
 
 
0.89-2.55 
 
 
0.129 
 
 
1.06 
 
 
0.60-1.86 
 
 
0.838 
Lab Number:       
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0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
1.47 
0.43 
1.37 
0.76 
0.95 
 
0.94-2.30 
0.15-1.21 
0.57-3.26 
0.17-3.35 
0.27-3.34 
 
0.088 
0.110 
0.477 
0.716 
0.934 
 
1.31 
0.32 
1.07 
0.65 
0.86 
 
0.82-2.08 
0.11-0.95 
0.43-2.65 
0.14-2.93 
0.23-3.19 
 
0.340 
0.081 
0.996 
0.495 
0.619 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.23 
1.73 
 
 
 
0.87-1.73 
1.31-2.28 
 
 
 
0.232 
<0.001 
 
 
 
1.27 
1.61 
 
 
 
0.89-1.82 
1.15-2.25 
 
 
 
0.182 
0.05 
Vaccines 0.91 0.62-1.33 0.628 0.69 0.46-1.05 0.084 
Drugs For Acid 
Related Disorders 
1.41 0.99-2.01 0.057 1.06 0.72-1.56 0.755 
Respiratory Med 1.48 1.04-2.11 0.029 0.98 0.66-1.47 0.931 
Lipid Medications 1.46 1.03-2.07 0.033 1.16 0.76-1.75 0.492 
Heart Failure 3.04 0.55-16.81 0.202 1.42 0.20-10.18 0.727 
Fatty Liver 
Disease 
- - - - - - 
Obesity 1.84 0.78-4.33 0.161 1.30 0.53-3.18 0.570 
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Musculoskeletal Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.01 0.77-1.33 0.915 1.06 0.77-1.47 0.714 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.65 
0.80 
1.45 
 
0.90 
0.30 
 
0.46-0.90 
0.57-1.11 
1.07-1.97 
 
0.63-1.28 
0.16-0.56 
 
0.010 
0.175 
0.017 
 
0.560 
<0.001 
 
0.68 
0.82 
1.47 
 
0.97 
0.29 
 
0.48-0.97 
0.58-1.16 
1.07-2.02 
 
0.67-1.40 
0.16-0.55 
 
0.013 
0.246 
0.022 
 
0.524 
<0.001 
Sex (Female) 0.62 0.50-0.77 <0.001 0.61 0.49-0.76 <0.001 
Microvascular 2.10 0.74-5.94 0.163 1.81 0.59-5.49 0.296 
Macrovascular 0.67 0.23-1.92 0.459 0.87 0.29-2.60 0.800 
Respiratory 
Disease 
1.60 1.27-2.03 <0.001 1.23 0.91-1.65 0.175 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
1.83 
 
 
1.17-2.85 
 
 
0.007 
 
 
1.31 
 
 
0.81-2.12 
 
 
0.271 
Referral: 
0-1 
≥2 
 
 
1.67 
 
 
1.08-2.58 
 
 
0.021 
 
 
1.31 
 
 
0.83-2.09 
 
 
0.247 
Lab Number:       
 184 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
0.73 
1.21 
0.90 
0.86 
0.73 
 
0.46-1.15 
0.70-2.09 
0.41-1.97 
0.25-2.95 
0.28-1.89 
 
0.174 
0.496 
0.803 
0.810 
0.516 
 
0.65 
1.03 
0.79 
0.52 
0.46 
 
0.40-1.05 
0.58-1.84 
0.35-1.75 
0.14-1.93 
0.17-1.24 
 
0.078 
0.921 
0.558 
0.329 
0.125 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.06 
1.62 
 
 
 
0.78-1.43 
1.28-2.05 
 
 
 
0.726 
<0.001 
 
 
 
0.96 
1.35 
 
 
 
0.70-1.33 
1.02-1.79 
 
 
 
0.830 
0.036 
Vaccines 0.86 0.62-1.20 0.370 0.82 0.57-1.16 0.267 
Drugs For Acid 
Related Disorders 
1.92 1.45-2.56 <0.001 1.68 1.22-2.30 0.001 
Respiratory Med 1.63 1.21-2.18 0.001 1.11 0.79-1.56 0.553 
Lipid Medications 1.25 0.92-1.71 0.152 1.31 0.90-1.92 0.160 
Heart Failure - - - - - - 
Fatty Liver 
Disease 
1.78 0.37-8.61 0.475 1.69 0.33-8.54 0.528 
Obesity 1.57 0.83-2.99 0.167 1.26 0.64-2.50 0.503 
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Viral Infections:  
 
Variable Crude 
OR 
95%CI P value Adjusted 
OR 
95%CI P value 
Diabetes 1.42 0.95-2.13 0.086 1.33 0.80-2.21 0.268 
Age: 
18-29 Years 
30-39 Years 
40-49 Years 
50-59 Years 
60-69 Years 
≥70 Years 
 
0.52 
0.49 
0.83 
 
0.60 
0.58 
 
0.31-0.87 
0.28-0.85 
0.50-1.37 
 
0.33-1.08 
0.30-1.14 
 
0.013 
0.012 
0.466 
 
0.091 
0.114 
 
0.52 
0.48 
0.85 
 
0.55 
0.60 
 
0.29-0.91 
0.26-0.89 
0.50-1.46 
 
0.29-1.04 
0.29-1.26 
 
0.023 
0.019 
0.557 
 
0.067 
0.177 
Sex (Female) 0.91 0.64-1.29 0.602 0.83 0.57-1.20 0.324 
Microvascular 11.92 1.07-132.18 0.043 5.39 0.41-70.53 0.199 
Macrovascular - - - - - - 
Respiratory 
Disease 
1.90 1.30-2.78 0.001 1.88 1.14-3.11 0.014 
Doctor Visits: 
≤12 Visits 
>12 Visits 
 
 
1.27 
 
 
0.53-3.07 
 
 
0.593 
 
 
1.10 
 
 
0.41-2.97 
 
 
.852 
Referral: 
0-1 
≥2 
 
 
0.76 
 
 
0.27-2.16 
 
 
0.609 
 
 
0.55 
 
 
0.17-1.74 
 
 
0.308 
Lab Number:       
 186 
0-29 
30-59 
60-89 
90-119 
120-149 
≥150 
 
0.83 
0.83 
0.40 
1.67 
- 
 
0.43-1.60 
0.31-2.17 
0.05-3.12 
0.34-8.18 
- 
 
0.578 
0.701 
0.383 
0.524 
- 
 
0.77 
0.54 
0.30 
1.74 
- 
 
0.38-1.56 
0.18-1.55 
0.04-2.50 
0.33-9.20 
- 
 
0.469 
0.251 
0.268 
0.511 
- 
Infection Before 1 
Year Of Entry: 
0 
1 
≥2 
 
 
 
1.29 
1.40 
 
 
 
0.81-2.06 
0.94-2.09 
 
 
 
0.274 
0.093 
 
 
 
1.27 
1.23 
 
 
 
0.76-2.13 
0.74-2.04 
 
 
 
0.364 
0.419 
Vaccines 1.83 1.17-2.87 0.008 2.05 1.24-3.39 0.005 
Drugs For Acid 
Related Disorders 
1.30 0.78-2.15 0.315 0.98 0.55-1.74 0.957 
Respiratory Med 1.19 0.70-2.02 0.528 0.60 0.31-1.15 0.125 
Lipid Medications 1.22 0.72-2.04 0.457 0.97 0.51-1.83 0.922 
Heart Failure - - - - - - 
Fatty Liver 
Disease 
17.09 1.76-165.65 0.014 19.24 1.81-
204.58 
0.005 
Obesity 3.77 1.59-8.95 0.003 2.22 1.26-8.25 0.015 
 
 
 
 
 
 
